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 Coagulase positive staphylococci, Staphylococcus aureus and Staphylococcus 
pseudintermedius, are important causes of infection in human beings and dogs respectively.  The 
rapid increase in the incidence of methicillin resistant S. aureus (MRSA) in people and its 
emergence in dogs has raised the profile of this organism in the veterinary community.  
Similarly, human S. pseudintermedius infections have also been recognized as the awareness of 
bidirectional human-dog transmission increases.   
 Antimicrobial resistance has been complicating the treatment of S. aureus infections 
since the first penicillin resistance was observed in the 1940s.  Methicillin resistance (resistance 
to the majority of β-lactams), is particularly troublesome as the β-lactams are a safe and effective 
class of antimicrobials for treating susceptible staphylococcal infections in both human beings 
and dogs.  Additionally, resistance to other antimicrobial classes such as the macrolides, 
tetracyclines, sulfonamides and chloramphenicol, further complicates the treatment of 
staphylococcal infections.  Particularly in small animal private practice, infections are often 
treated empirically, requiring knowledge of locally prevalent susceptibility patterns.  The 
emergence of resistance to commonly used drugs necessitates surveillance to monitor the 
dissemination of resistance, and to guide antimicrobial therapy. 
 In the last decade there have been many studies attempting to address gaps in our 
knowledge of the ecology of S. aureus and S. pseudintermedius in dogs.  In particular, the 
prevalence of colonization with methicillin resistant staphylococci has been documented in 
different dog populations.  However, failing to sample all relevant sites of colonization, may 
have decreased the sensitivity of these studies.  The sites where coagulase positive staphylococci 
colonize dogs have not been systematically evaluated.   
 iii 
 
 The clinical and infection control implications of S. aureus infections, or colonization in 
the case of MRSA, requires timely laboratory identification.  The tube coagulase test is arguably 
the most important tool used for identifying of staphylococcal species.  Studies dating from the 
1970s and 1980s suggested that the use of rabbit plasma, which is the current standard, may not 
be the ideal media for all situations and that different plasmas may need to be considered in 
different diagnostic situations.   
 In this thesis, the ecology of coagulase positive staphylococci in dogs was studied from 
start to finish including sample collection, bacterial identification, antimicrobial susceptibility 
testing and molecular epidemiological investigations.  This thesis will serve as a template to be 
used for follow up studies or by investigators setting up a surveillance program in their region. 
 We found that multiple sites of colonization (nares, pharynx and rectum), are involved in 
both S. aureus and S. pseudintermedius carriage in dogs.  Single site colonized dogs were 
identified, suggesting that maximal screening sensitivity requires sampling multiple body sites.  
When canine and rabbit plasma were compared, the time until clot formation was found to be 
significantly shorter with canine plasma.  Although, the availability of canine plasma may limit 
its use in the diagnostic laboratory, investigators should be aware that rabbit plasma may not be 
ideal for all applications of the tube coagulase test.  Antimicrobial susceptibility testing of canine 
S. aureus and S. pseudintermedius and human S. aureus isolates was done.  Consistent with 
previous reports from Saskatoon, the S. pseudintermedius isolates were found to be 
overwhelmingly susceptible: pan-susceptibility was the most common phenotype identified.  
Antimicrobial resistance was more common among S. aureus than S. pseudintermedius including 
resistance to drugs which all S. pseudintermedius were susceptible to.  No resistance to 
vancomycin, linezolid, daptomycin or quinupristin/dalfopristin was found.  All isolates remained 
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susceptible to at least one of tetracycline, clindamycin, chloramphenicol or 
trimethoprim/sulfamethoxazole which are often used for treating infections caused by multidrug 
resistant staphylococci.  Finally, DNA fingerprinting revealed that the canine and human S. 
aureus isolates tested did not belong to mutually exclusive populations.  Using AFLP, IS-typing 
and spa typing, many human and canine isolates were indistinguishable suggesting a common 
population, supporting the hypothesis that interspecies transmission occurs. 
 The complex and under-characterized ecology of S. aureus and S. pseudintermedius 
requires more study so that risk factors for infection can be defined and effective infection 
control measures implemented.  Because multiple species are involved, collaboration between 
veterinarians and human health professionals is imperative, and will no doubt yield the most 
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Chapter 1 - Literature Review 
1.1 Staphylococcus 
1.1.1 Taxonomy 
 Staphylococcus is a genus of Eubacteria in the phylum Firmicutes, class Bacilli, order 
Bacillales, family Staphylococcaceae (NCBI 2011).  These organisms are Gram positive coccoid 
bacteria, typically 0.5 – 1.5 µm in diameter (Winn, Allen et al. 2006). 
 The genus Staphylococcus is presently divided into 38 species, which are commonly 
divided by their ability to coagulate plasma (the coagulase test) (Van Hoovels, Vankeerberghen 
et al. 2006; Winn, Allen et al. 2006).  The coagulase negative staphylococci are further 
subdivided by their susceptibility to novobiocin (Winn, Allen et al. 2006). 
 As the most clinically important staphylococcal species in humans, S. aureus has been 
extensively studied (Winn, Allen et al. 2006).  In dogs, S. pseudintermedius is the most common 
coagulase positive species, playing an analogous role in dogs to S. aureus in people.  Other 
coagulase positive staphylococci include S. intermedius and S. delphini (of the Staphylococcus 
intermedius group, SIG, along with S. pseudintermedius), S. hyicus and S. lutrae (Foster, Ross et 
al. 1997; Winn, Allen et al. 2006).   
 
1.1.2 Identification 
1.1.2.1 Biochemical identification 
 While S. aureus and S. pseudinteremdius are the most important etiological agents 
identified from skin and soft tissue infection in human beings and canine pyoderma, the lack of a 
pathognomonic presentation necessitates laboratory diagnostics (Moet, Jones et al. 2007; 




grow on minimal media and sheep blood agar (Winn, Allen et al. 2006).  Staphylococcus aureus 
can easily be biochemically differentiated from SIG species, including S. pseudintermedius 
(Table 1.1). 
 On sheep blood agar S. aureus and S. pseudintermedius grow as round 1-3 mm colonies 
which are creamy white-yellow, low convex and with few exceptions β-hemolytic (Van Hoovels, 
Vankeerberghen et al. 2006; Winn, Allen et al. 2006).  S. aureus often produces two zones of 
hemolysis; this phenotype is less frequent with S. pseudintermedius (Cole 1990).  
Microscopically, staphylococci form characteristic “grape like clusters” (Anderson 2003; Winn, 
Allen et al. 2006).   
 The catalase test can be used to differentiate staphylococci (positive) from other Gram-
positive cocci (negative) (Winn, Allen et al. 2006).  A positive catalase test results from the 
presence of cytochrome oxidase enzymes found in staphylococci and micrococci, but not 
streptococci or enterococci (Winn, Allen et al. 2006). 
 Coagulase positive and negative staphylococci are differentiated using the tube coagulase 
test (Winn, Allen et al. 2006).  Tubes containing plasma are inoculated with test organism, 
incubated at 35°C and observed for visible clot formation which indicates a positive test (Winn, 
Allen et al. 2006).  The slide agglutination test can also be used, although the lower sensitivity of 
this test for S. pseudintermedius than S. aureus may result in false negatives in veterinary 
diagnostic labs (Cox, Newman et al. 1985; Winn, Allen et al. 2006).  Commercially available 
rabbit plasma is most commonly used for the coagulase test (Winn, Allen et al. 2006).  Although 
the availability of high quality rabbit plasma is convenient, it is not necessarily the best medium, 
the sensitivity of this test may be increased by using other plasmas in some scenarios (Orth, 




Table 1.1 Biochemical differentiation of S. aureus and S. pseudintermedius 
Biochemical Test S. aureus S. pseudintermedius Reference 
Hemolysis Double zone β-hemolytic (Cole 1990) 
Catalase + + (Cole 1990; Van Hoovels, 
Vankeerberghen et al. 2006) 
Coagulase + + (Cole 1990; Van Hoovels, 
Vankeerberghen et al. 2006) 
DNase + + (Cole 1990; Van Hoovels, 
Vankeerberghen et al. 2006) 
Mannitol Fermentation + + (Talan, Staatz et al. 1989; Cole 
1990) 
Acetoin + - (Talan, Staatz et al. 1989; 
Pottumarthy, Schapiro et al. 2004) 
Hyaluronidase + - (Devriese, Nzuambe et al. 1984)

















different host species have been shown to coagulate different plasmas with varying 
efficiency (Live 1972; Adesiyun and Shehu 1985).  Staphylococcus pseudintermedius coagulase 
activity may be similarly fickle in its reaction to different plasmas, although the limited evidence 
available suggests that rabbit plasma may be adequate (Cox, Newman et al. 1985).  This 
variability has been attributed to factors intrinsic to the plasma or characteristics of the test 
isolate.  The amount of coagulase reacting factor among plasmas is intrinsic to each plasma, 
while the interaction between an organism’s coagulase and different plasmas is organism specific 
(Orth, Chugg et al. 1971).  Inconsistencies in the time to clot formation and fibrinolytic activity 
between isolates can complicate the identification of positive samples (Orth, Chugg et al. 1971).  
Coagulation times of isolates collected during this study ranged from 1-24 hours.  Some 
fibrinolytic isolates, which were also fast coagulators, produced and dissolved a clot within eight 
hours.  Without careful observation, this variability in coagulase/fibrinolysin activity between 
isolates could result in false negative results.   
 Coagulase negative staphylococci are often categorized as novobiocin susceptible or 
resistant.  Staphylococcus saprophyticus a common cause of urinary tract infections in people 
and the most clinically relevant novobiocin-resistant species may be presumptively identified 
with that test (Winn, Allen et al. 2006).  As these organisms are not within the scope of this 
thesis, their identification will not be discussed further.   
 Coagulase positive staphylococci can be further divided based on polymyxin B 
susceptibility.  Polymyxin B resistance, defined as a Kirby-Bauer zone of inhibition less than 
10mm using a 30µg disc, is characteristic of S. aureus (Winn, Allen et al. 2006).  Staphylococcus 




 Production of acetoin, detected with the Voges-Proskauer test, aids in differentiation of S. 
aureus from S. pseudintermedius since S. aureus produces acetoin while SIG species do not (Van 
Hoovels, Vankeerberghen et al. 2006; Winn, Allen et al. 2006; Sasaki, Kikuchi et al. 2007).   
 The production of hyaluronidase is assessed by the interaction of a test isolate with a pure 
culture of Pasteurella multocida (S. equi has been previously reported) (Skalka 1985).  A P. 
multocida streak is made on blood agar and a line of the test organism is then inoculated  
adjacent to the P. multocida streak at 90° without touching it (Carter and Rundell 1975). When a 
mucoid P. multocida isolate is used, S. aureus will result in a deviation of normal P. multocida 
colony morphology (flattened, non-mucoid growth) (Carter and Rundell 1975).  Hyaluronidase 
production is useful for differentiating S. aureus (positive), from SIG species (negative) 
(Devriese, Nzuambe et al. 1984).  There is a paucity of data in the literature regarding this test 
for the identification of staphylococci; but it has been useful in the diagnostic setting at the 
Western College of Veterinary Medicine (Chirino-Trejo 2011).  In this study, hyaluronidase test 
results have been corroborated by other biochemical tests and sequence based techniques.   
 The production of DNase, a characteristic of coagulase positive staphylococci, can be 
detected with DNase solid agar (Winn, Allen et al. 2006).  Staphylococcus aureus and S. 
pseudintermedius are DNase positive, distinguishing them from coagulase negative species (Van 
Hoovels, Vankeerberghen et al. 2006).   
 Bacterial species vary in their capacity to ferment carbohydrates, and fermentation of a 
given sugar is a commonly defined biochemical characteristic.  When added to a minimal 
medium as the sole carbohydrate source, fermentation results in acidification which can be 




 Selective and differential media allow rapid presumptive identification of organisms of 
clinical importance: CHROMagar MRSA, mannitol salt agar + cefoxitin, MRSA select and 
MRSA screen are several examples (Bischof, Lapsley et al. 2009; Graveland, van Duijkeren et 
al. 2009).  Furthermore, antimicrobials such as oxacillin or cefoxitin can be incorporated into 
media to allow selective culture of methicillin resistant isolates (CLSI 2008).    
 While S. aureus can be readily identified by biochemical means, species within the S. 
intermedius group (S. intermedius, S. pseudintermedius and S. delphinii) are not biochemically 
distinct from one another (Sasaki, Kikuchi et al. 2007; Bannoehr, Franco et al. 2009; Devriese, 
Hermans et al. 2009; Weese and van Duijkeren 2010).  Biochemical identification of S. 
intermedius group species combined with knowledge of host species allows a presumptive 
species identification.  For example canine SIG isolates are assumed to be S. pseudintermedius 
(Devriese, Hermans et al. 2009; Weese and van Duijkeren 2010).  Molecular testing is required 
to differentiate definitively between species within the S. intermedius group (Devriese, 
Vancanneyt et al. 2005; Bannoehr, Franco et al. 2009; Weese and van Duijkeren 2010). 
 
1.1.2.2 Molecular identification 
 Sequence based techniques are objective, sensitive, specific and increasingly cost 
effective tools for bacterial identification.  Classical identification of bacteria requires 
maintaining an extensive inventory of test media or commercially prepared biochemical test 
panels.  Commercially prepared media packages such as API were developed for use in human 
clinical microbiology laboratories and are not designed to identify all organisms of interest to the 
veterinary or research microbiologist (Winn, Allen et al. 2006).  Differentiation of coagulase 




species is difficult-to-impossible and expensive using phenotypic techniques (Weese and van 
Duijkeren 2010).  For example API Staph, a kit costing approximately $9 produced by 
BioMerieux (Marce l’Etoile, France) is useful for identifying common human pathogens, but is 
of little value for many coagulase negative staphylococci and closely related taxa, or the SIG 
organisms (Van Hoovels, Vankeerberghen et al. 2006; Winn, Allen et al. 2006; Rubin and 
Chirino-Trejo 2010).  In the last decade, the cost of DNA sequencing has dramatically decreased 
making sequence based methods an attractive alternative to commercially available kits for 
identifying organisms.   
 The gene encoding the small subunit ribosomal RNA (16S rRNA) is universal among 
bacteria (Harmsen, Rothganger et al. 2002).  The 16S rRNA gene is slow to evolve, resulting in 
little variation between isolates related at the species/genus level (Harmsen, Rothganger et al. 
2002).  Sequencing of the 16S rRNA gene yields a sequence which when compared with a 
database allows identification of the isolate to a clinically relevant level for many organisms, 
although not for Staphylococcus species (Harmsen, Rothganger et al. 2002).  Historically, 16S 
rRNA has been the gene of choice for phylogenetic studies and has become entrenched as a 
benchmark method despite the discovery of higher resolution target sequences such as the gene 
encoding the Hsp60 chaperonin (cpn60) (Goh, Potter et al. 1996; Kwok and Chow 2003).   
 The cpn60 sequence has superior resolution for differentiating closely related coagulase 
negative staphylococci and SIG species (Goh, Santucci et al. 1997; Devriese, Hermans et al. 
2009).  In the experiments comprising this thesis, an organism grown on CHROMagar + 4μg/mL 
oxacillin that was morphologically indistinguishable from S. aureus but biochemically 
unidentifiable was investigated.  Using the API system, this isolate was identified as 




to Macrococcus caseolyticus (Rubin and Chirino-Trejo 2010).  Sequencing of the cpn60 gene 
revealed that, while the most closely related organism is M. caseolyticus, with only 89% 
sequence identity it is most likely a novel species (Rubin and Chirino-Trejo 2010). 
 Other techniques involve sequencing genus specific genes such as sodA and fem for 
species identification (Vannuffel, Gigi et al. 1995; Sasaki, Kikuchi et al. 2007; Weese and van 
Duijkeren 2010). 
 
1.2 Staphylococcus aureus 
1.2.1 Colonization 
1.2.1.1 Human colonization 
 Staphylococcus aureus commonly colonizes mucosal surfaces of human beings 
(Kluytmans-Vandenbergh and Kluytmans 2006; Winn, Allen et al. 2006).  The point prevalence 
of nasal colonization is frequently reported to be approximately 30% (Kuehnert, Kruszon-Moran 
et al. 2006; Gorwitz, Kruszon-Moran et al. 2008).  However, a binary definition is inadequate to 
describe the complexity of colonization dynamics.  Three general populations (of human beings) 
are recognized: those who are persistently colonized, intermittently colonized and non-colonized 
(Kluytmans and Wertheim 2005).  Approximately 10-35% of human beings are persistently 
colonized, 20-70% are intermittently colonized and a further 5-50% are non-colonized 
(Kluytmans and Wertheim 2005; Wertheim, Melles et al. 2005; Hamdan-Partida, Sainz-Espunes 
et al. 2010).   
 Persistently colonized individuals tend to have their “own” strain; which is particularly 
adapted to colonize that individual (Hamdan-Partida, Sainz-Espunes et al. 2010). Since an 




colonization is a risk factor for infection (Wertheim, Vos et al. 2004).  This risk factor 
necessitates screening for colonization so that preventive measures can be implemented to reduce 
the risk of infection following high risk medical procedures (Coates, Bax et al. 2009; de Smet, 
Kluytmans et al. 2009; Kluytmans and Harbarth 2009).  Despite an increased risk of infection, 
colonized individuals are more likely to survive a systemic S. aureus infection than non-
colonized persons (Wertheim, Vos et al. 2004; Wertheim, Melles et al. 2005).  This protective 
effect is hypothesized to be due to the immunological priming effect of colonization (Wertheim, 
Vos et al. 2004). 
 While the nares have historically been recognized as an important site of S. aureus 
colonization, the role of other sites has recently been quantified (Mody, Kauffman et al. 2008).  
The pharynx, intestinal tract, perineum and axilla are recognized as potential sites of 
colonization, including single site colonized individuals (Mertz, Frei et al. 2007; Batra, Eziefula 
et al. 2008; Mody, Kauffman et al. 2008; Yang, Tan et al. 2009).  Because the nares are not the 
primary site of colonization in every individual, successful elimination of S. aureus carriage may 
require decolonization of extra-nasal sites (Ammerlaan, Kluytmans et al. 2009; McConeghy, 
Mikolich et al. 2009).  Single site S. aureus or MRSA colonization of the pharynx among 
colonized individuals has been reported in 9.3-21.8% of patients (Mertz, Frei et al. 2007; Mody, 
Kauffman et al. 2008; Ide, Lootens et al. 2009).  Similarly, 8-31% of people have been shown to 
be enterally colonized, and among those colonized with MRSA, 8% were exclusively enterally 
colonized (Acton, Tempelmans Plat-Sinnige et al. 2008; Batra, Eziefula et al. 2008). 
 




 Compared to our knowledge of colonization of human beings, much less is known about 
canine S. aureus colonization.  Although most studies have focused on MRSA, the few studies 
investigating overall S. aureus colonization have found prevalences of 8.8-12% (Boost, 
O'Donoghue M et al. 2007; Griffeth, Morris et al. 2008).  Recognizing the potential importance 
of multiple colonization sites, the skin, nares, pharynx and rectum have been included in 
prevalence studies; however a systematic comparison of these or other sites has not been done 
(Boost, O'Donoghue M et al. 2007; Griffeth, Morris et al. 2008; Nienhoff, Kadlec et al. 2009; 
Weese and van Duijkeren 2010).   
 
1.2.2 S. aureus as a human pathogen 
1.2.2.1 Common syndromes 
 Staphylococcus aureus is a common cause of both community and healthcare (hospital, 
long-term care facility, etc.) associated infections.  As an opportunistic pathogen, S. aureus 
enters normally protected body sites that become exposed, or when host defenses are 
compromised (Gordon and Lowy 2008).  
 Skin and soft tissue infection (SSTI) is the most common infectious syndrome produced 
by S. aureus, and S. aureus is the most common cause of SSTI (Moet, Jones et al. 2007).  When 
these infections are localized and superficial treatment often requires only wound management 
including incision and drainage and topical antimicrobials (Barton, Hawkes et al. 2006).  Lesions 
with a “spider-bite” or “pimple” appearance, a reddened area with a necrotic centre containing 
purulent material, are the archetypal community associated MRSA (CA-MRSA ) SSTI and are 
more frequently caused by MRSA than other bacteria (Moran, Krishnadasan et al. 2006; Gorwitz 




 Staphylococcus aureus is one of the most common causes of hospital acquired infections, 
and in recent decades has become the most common cause of septicemia (Rice 2006; Klein, 
Smith et al. 2007).   
 
1.2.2.2 S. aureus virulence factors  
 Staphylococcus aureus carries a formidable array of virulence factors allowing it to cause 
a wide variety of infectious syndromes and intoxications (Table 1.2) (Archer 1998; Gordon and 
Lowy 2008). 
 
1.2.2.2.1 Panton Valentine Leukocidin 
 Panton Valentine leukocidin (PVL), a toxin associated with community-associated 
MRSA (CA-MRSA), has been studied intensively as the incidence of CA-MRSA has increased 
(Boyle-Vavra and Daum 2007).  While the role of PVL in pathogenesis has been somewhat 
controversial and recent evidence suggests that its contribution to disease was overstated, it is at 
least epidemiologically related to the archetypal CA-MRSA clone, USA300 (Kennedy, Otto et 
al. 2008; Lalani, Federspiel et al. 2008; Otto 2011). 
 Panton Valentine leukocidin is a heteromultimer encoded by the LukS-PV and LukF-PV 
genes (Lina, Piemont et al. 1999; Labandeira-Rey, Couzon et al. 2007).  Like other toxins, the 
acquisition of PVL by S. aureus has been associated with phage transduction (Wolter, Tenover et 
al. 2007).  The expression of PVL is not constitutive and may be affected by cell density (via 
quorum sensing) or phagocytosis by neutrophils (Loffler, Hussain et al. 2010).  Quorum sensing 
is a process by which bacteria detect and respond to their density in their environment (Dancer 




Table 1.2 Summary of S. aureus virulence factors 
Toxins  Effect and Syndromes  Reference 
Staphylococcal Enterotoxins 
(SEA-E, SEG-R and SEU 
Super-antigen 
   -Staphylococcal enterocolitis 
   -Food poisoning 
   -Toxic shock syndrome 
(Winn, Allen et al. 2006; Baba-
Moussa, Anani et al. 2008; 
Vaishnani 2009; Lin, Kotler et 
al. 2010; Stow, Douglas et al. 
2010) 
Toxic Shock Syndrome Toxin 
íTSST-1) 
Super-antigen 
   -Toxic shock syndrome 
(Winn, Allen et al. 2006; Baba-





   -Bullous impetigo 
   -Staphylococcal scalded skin 
    syndrome 
   -Blistering 
(Prevost, Couppie et al. 2003; 
Winn, Allen et al. 2006; Baba-




   -Necrotic processes 
   -Necrotizing pneumonia 
   -CA-MRSA infections 
(Labandeira-Rey, Couzon et al. 
2007; Baba-Moussa, Anani et al. 
2008; Loffler, Hussain et al. 
2010) 
Staphylococcal protein A 
(SpA) 
Super-antigen 
Interfering with immune  
response   
(Archer 1998; Winn, Allen et 











 accessory gene regulator (agr), which coordinates the cells transcriptional activity and can be 
turned on or off as appropriate (Dancer 2008; Boyen, Eeckhaut et al. 2009).   
 While in vitro experiments have demonstrated that PVL is active against human 
neutrophils, the species specificity of its activity is ill defined (Loffler, Hussain et al. 2010).   In 
vitro experiments that aimed to determine the role of PVL in different infectious syndromes were 
confounded by the variable activity of PVL against neutrophils from different animal species 
(Loffler, Hussain et al. 2010).  This specificity became apparent when in vivo models and in vitro 
experiments using non-human tissues yielded conflicting results (Loffler, Hussain et al. 2010).  
While PVL was found to potentiate osteomyelitis in a rabbit model it was ineffective against 
mouse and Java monkey neutrophils (Labandeira-Rey, Couzon et al. 2007; Cremieux, 
Dumitrescu et al. 2009; Loffler, Hussain et al. 2010).  Although the activity of PVL against 
canine neutrophils has not been experimentally determined, the scarsity of PVL positive S. 
aureus isolated from dogs suggests that it does not play a role in the pathogenesis of canine 
infections (Weese, Faires et al. 2007). 
 The role of PVL is best understood in human beings, where it is believed to be involved 
in the pathogenesis of necrotizing pneumonia and other necrotic processes (Lina, Piemont et al. 
1999; Labandeira-Rey, Couzon et al. 2007).  Staphylococcus aureus necrotizing pneumonia is 
most frequently caused by the hypervirulent (PVL positive) USA300 MRSA strain (Labandeira-
Rey, Couzon et al. 2007; Larsen, Stegger et al. 2007; Lalani, Federspiel et al. 2008; Simor, 
Gilbert et al. 2010). Panton Valentine leukocidin positive MRSA are also implicated in necrotic 
furunculosis (Lina, Piemont et al. 1999).  Outbreaks (transmission) of SSTI caused by PVL 
positive MRSA have been reported following direct skin-to-skin contact or contact with 




2008; Huijsdens, Janssen et al. 2008).  Some have speculated that PVL may indirectly promote 
transmission of MRSA by upregulating the expression of adhesive proteins or increasing 
bacterial shedding (Lina, Piemont et al. 1999; Boyle-Vavra and Daum 2007).  Interestingly, new 
evidence suggests that the importance of PVL, even in human infections, has been overestimated 
(Otto 2011). 
 
1.2.3 S. aureus as a veterinary pathogen 
1.2.3.1 Canine S. aureus infections 
 Staphylococcus aureus is likely under-recognized as a cause of infections in dogs.  Based 
on colony morphology it is difficult to differentiate S. aureus and S. pseudintermedius on both 
non-selective and some differential media.  Because S. pseudintermedius is the most common 
coagulase positive species isolated from dogs, presumptive identification based on a positive 
coagulase test could result in misidentifying S. aureus as S. pseudintermedius (Van Hoovels, 
Vankeerberghen et al. 2006). 
 The emergence of MRSA in dogs has raised awareness of non-pseudintermedius 
coagulase positive species in dogs and focused attention on accurate species specific 
identification (Weese and van Duijkeren 2010).  Staphylococcus aureus seems to easily 
substitute for S. pseudintermedius; given the opportunity it will cause otitis externa, pyoderma, 
post-surgical and other hospital acquired infections (Kwon, Park et al. 2006; Jones, Kania et al. 







1.2.3.2 S. aureus infections in other species 
 Staphylococcus aureus is promiscuous in its ability to colonize and cause infections in a 
wide range of hosts (Table 1.3).  Staphylococcus aureus mastitis, infection of the mammary 
gland leading to increased somatic cell counts in milk, is the single largest cause of economic 
loss to the North American dairy industry (Erskine 2001; Morin 2009).  Sub-clinical mastitis 
caused by S. aureus is an insidious condition resulting in decreased milk production, that without 
active surveillance may go un-noticed (Morin 2009).  Lapses in hygiene can facilitate 
transmission of S. aureus between cows via shared milking equipment (Morin 2009).  Other  
species including horses and avian species are also commonly infected or colonized with S. 
aureus (Rubin, Ball et al. 2011).  In chickens, foot and leg infections (bumblefoot) are 
commonly caused by S. aureus (White, Ayers et al. 2003; Lowder, Guinane et al. 2009).  Equine 
S. aureus colonization and hospital associated infections (following arthroscopy or intravenous 
catheterization), and superficial skin infections are recognized (Devriese, Nzuambe et al. 1985; 
Weese, Rousseau et al. 2006; Sung, Lloyd et al. 2008). 
 
1.2.4 The history and development of antimicrobial resistance in S. aureus 
1.2.4.1 The early years – S. aureus before antibiotics  
 With the development of germ theory, preventive measures were recognized to be the 
best defense against hospital acquired infections following surgery.  Early treatments for severe 
S. aureus infections required creativity and included the transfusion of “immune blood”, a 
procedure which with our current knowledge of bloodborne pathogens would best be avoided 
(Hooker 1917).  In the pre-antibiotic era, infections carried a much higher risk of mortality than 




Table 1.3 Animals in which S. aureus has been identified 
Animal  Reference 
Bat (Walther, Wieler et al. 2007) 
Bison (Rubin, Ball et al. 2011) 
Cat (Rankin, Roberts et al. 2005; Leonard and Markey 2008) 
Cow (Leonard and Markey 2008) 
Caribou (Rubin, Ball et al. 2011) 
Chicken (Leonard and Markey 2008) 
Dog (Rankin, Roberts et al. 2005; Walther, Wieler et al. 2007; Leonard and Markey 2008) 
Dolphin (Faires, Gehring et al. 2009; Schaefer, Goldstein et al. 2009) 
Elephant (CDC 2009) 
Goat (Rubin, Ball et al. 2011) 
Guinea Pig (Walther, Wieler et al. 2007) 
Horse (Leonard and Markey 2008) 
Iguana (Rubin, Ball et al. 2011) 
Meercat (Rubin, Ball et al. 2011) 
Mouse (Rubin, Ball et al. 2011) 
Parrot (Rankin, Roberts et al. 2005; Walther, Wieler et al. 2007) 
Pigeon (Losito, Vergara et al. 2005) 
Pig (Leonard and Markey 2008) 
Rabbit (Rankin, Roberts et al. 2005; Walther, Wieler et al. 2007; Leonard and Markey 2008) 
Rat (Rubin, Ball et al. 2011) 
Seal (Leonard and Markey 2008) 
Sea Otter (Rubin, Ball et al. 2011) 
Sheep (Leonard and Markey 2008; Rubin, Ball et al. 2011) 
Tilapia (Atyah, Zamri-Saad et al. 2011) 
Turtle (Walther, Wieler et al. 2007) 
Walrus (Faires, Gehring et al. 2009) 








a decrease in the mortality rate associated with staphylococcal bacteremeia from 70% to 25% in 
the early 1940s (Dancer 2008).  Some have credited antimicrobials for a 10 year increase in the 
average life expectancy (McDermott and Rogers 1982). 
 
1.2.4.2 The introduction of penicillin, and the first resistance  
 Penicillin was discovered in 1928 after Sir Alexander Fleming observed the inhibitory 
action of Penicillium notatum on bacterial cultures and hypothesized the presence of an 
inhibitory substance (Aronson 1992; Bryskier 2005).  This work, along with that of Ernst Borris 
and Howard Walter Florey began the antibiotic age, revolutionizing modern medicine.  Their 
contributions were recognized with a Nobel Prize in 1945 (NobelMedia 2011).  When it was first 
used clinically in the United States in 1942, penicillin was touted as a wonder drug whose use 
was limited only by manufacturing capacity (Grossman 2008).  Penicillin was used to treat 
gonorrhea, septicemia, pneumonia, infections following accidents and wounds in soldiers in 
WWII (Fraser 1974; Garrod 1974; Hey 1974; Fraser 1984).  Unfortunately, the evolutionary 
power of “the enemy” was not anticipated and the bacteria were already mounting a formidable 
defense. 
 In hospitals, where the selection pressure was most intense, S. aureus (known as S. 
pyogenes at the time) were quickly becoming resistant (Barber 1947).  In a 1947 report, Dr. 
Mary Barber, a bacteriologist in London, England, reported rapidly increasing penicillin 
resistance, describing it as “alarming” (Barber 1947).  Eleven years later she reported “S. 
pyogenes” resistant to penicillin, streptomycin, tetracycline, chloramphenicol and erythromycin 





“It is a neck-and-neck race in which many of us tend to underestimate the 
opponent.  Staphylococci will not be defeated by the haphazard use of each new 
antibiotic.  As new antibacterial agents are discovered, let us use them with 
discrimination.” (Barber and Burston 1955)   
 
The overwhelming success of penicillin resistant S. aureus led to their dominance over penicillin 
susceptible S. aureus in the community where they predominate today; in one study 94% of 
methicillin-susceptible S. aureus (MSSA) were penicillin resistant (Sa-Leao, Sanches et al. 
2001).  
 By the 1940s and 50s the antimicrobial arms race was in full swing; soil samples from 
every corner of the world were screened for new organisms and their potential antimicrobial 
products (Routien and Finlay 1952).  Tetracycline, streptomycin (which was the subject of the 
1952 Nobel Prize), chloramphenicol, erythromycin and vancomycin were introduced to counter 
the rapidly emerging resistance to penicillin and to treat those infections caused by organisms 
intrinsically resistant to penicillin, such as tuberculosis (Powers 2004; NobelMedia 2011). 
 
1.2.4.3 The introduction of methicillin and resistance emergence, 1960 – present 
 Methicillin, introduced as celbenin in 1960 was the first semi-synthetic penicillin 
developed (Woodford and Livermore 2009).  Semi-synthetic group M penicillins including 
methicillin, oxacillin and cloxacillin were developed to resist the hydrolytic activity of the S. 
aureus “penicillinase” which readily degrades penicillin (Barber 1961; Bryskier 2005).  The first 
report of MRSA, including three isolates, was published in the British Medical Journal in 1961 






1.2.4.3.1 What is Methicillin Resistance? 
 Methicillin resistance is not due to the production of a hydrolytic enzyme, unlike β-
lactamase mediated penicillin resistance (Woodford and Livermore 2009).  β-lactams (penicillin 
and methicillin) are cell wall synthesis inhibitors and act by binding to penicillin binding proteins 
(PBP) in the cell wall inhibiting peptidoglycan cross linking and leading to a defective cell wall 
(Bryskier 2005).  In MRSA, the mecA gene encodes an altered PBP2 (PBP2a) that has low β-
lactam affinity preventing the drug from binding to its target and bactericidal activity (Woodford 
and Livermore 2009).  As all β-lactams bind to PBP, MRSA are resistant to all currently 
available drugs in this class including the penicillins, potentiated penicillins (those with β-
lactamase inhibitors such as clavulanic acid), cephalosporins and carbapenems (Palavecino 
2007).   Methicillin resistance is a historical designation related to the first recognition of this 
resistance (resistance to methicillin) rather than the spectrum of resistance it confers (all β-
lactams). 
 The mecA gene is carried by the staphylococcal chromosomal cassette (SCC), which with 
mecA is known as SCCmecA (Chambers and Deleo 2009).  Among MRSA, the SCC is not a 
single distinct structure.  By 2009 at least eight SCC allotypes denoted by roman numerals and 
many subtypes indicated by lowercase letters had been recognized (Chambers and Deleo 2009).  
The widespread use of DNA sequencing has shed light on SCCmec diversity, leading to a rapidly 








Table 1.4 Characteristics associated with CA-MRSA and HA-MRSA 
Characteristic  CA‐MRSA  HA‐MRSA Reference 
PVL  Common Uncommon (Barton, Hawkes et al. 2006; 
Boyle-Vavra and Daum 2007) 
SCCmec types  IV, V I, II, III (Barton, Hawkes et al. 2006) 




(Barton, Hawkes et al. 2006) 
Resistance to  
other drugs 
Rare Common (Barton, Hawkes et al. 2006; 








(Barton, Hawkes et al. 2006; 
Millar, Loughrey et al. 2007) 
Associated 
syndromes 





Respiratory and urinary 
tract infections 
(Millar, Loughrey et al. 2007; 









associated risk factors 
Occur within 48 hours 
of hospitalization 
Previous hospitalization 
Occur  after more than 48 
hours of hospitalization 
Long term care facility 
residents 














1.2.4.3.2 Emergence of MRSA: its 50 year history 
1.2.4.3.3 Community versus hospital associated MRSA  
 MRSA infections are commonly classified as either community associated (CA-MRSA) 
or healthcare associated (HA) (Table 1.4).  Recently, highly successful CA-MRSA clones, 
(including USA300) which now cause the majority of CA-MRSA infections, have become 
established in hospitals and are an important cause of hospital acquired infections (Kluytmans-
Vandenbergh and Kluytmans 2006; Bartlett 2008; Arias and Murray 2009). The presence of 
historically CA-MRSA lineages in healthcare facilities in some cases replacing HA-MRSA 
strains is blurring the classical CA vs. HA definition (Millar, Loughrey et al. 2007). 
 
1.2.4.3.4 Emerging resistance and new therapies 
 Vancomycin, a glycopeptide discovered in 1956, has long been the mainstay of anti-
MRSA therapy (Bryskier and Veyssier 2005).  Because vancomycin has low oral bioavailability, 
intravenous access is required for administration (Bryskier and Veyssier 2005).  Glycopeptides, 
inhibit cell wall synthesis by a mechanism independent of PBP, and are therefore active against 
MRSA (Bryskier and Veyssier 2005; Palavecino 2007).  While glycopeptide resistance is not 
uncommon among Enterococcus faecalis (VRE), until recently even multidrug resistant MRSA 
remained susceptible (Bryskier and Veyssier 2005).  In 2002 the first vancomycin resistant S. 
aureus (VRSA) was isolated from a patient in Michigan and at least eight other cases have been 
recognized subsequently in the United States (CDC 2002; Finks, Wells et al. 2009).   
 Among VRE, vancomycin resistance is mediated by the van class of genes and vanA, 
conferring high level resistance, is the most common (Woodford and Livermore 2009).  The first 




colonizing VRE (Whitener, Park et al. 2004; Sievert, Rudrik et al. 2008).  Conjugative transfer of 
vanA from VRE to S. aureus has been achieved in vitro, supporting this hypothesis (Noble, 
Virani et al. 1992; Whitener, Park et al. 2004; Sievert, Rudrik et al. 2008).  More widespread 
than VRSA, vancomycin intermediate (VISA) isolates are also presenting clinical challenges.  
Elevated vancomycin MICs have been associated with increased resistance to other drugs, a 
higher rate of post surgical infections, longer duration of bacteremia and treatment failure 
(Soriano, Marco et al. 2008; Deresinski 2009; Maor, Hagin et al. 2009). 
 For MRSA infections in patients not requiring hospitalization, without IV access, or 
when the use of vancomycin is contraindicated, other treatment options are required.  Alternative 
therapies may include linezolid, the fluoroquinolones, macrolides/lincosamides, tetracyclines, 
sulfonamides or topically applied drugs such as mupirocin or fusidic acid (Walker, Dresser et al. 
2006; Drekonja, Traynor et al. 2008; Enoch, Karas et al. 2009; Tattevin, Basuino et al. 2009). 
 The fluoroquinolones are commonly prescribed by both veterinarians and physicians, and 
offer many advantages including infrequent dosing, good tissue penetration and rapid 
bactericidal activity (Walker and Dowling 2006).  Unfortunately, fluoroquinolone resistance has 
become common among MRSA, and at least in part due to this resistance, the use of these drugs 
has been identified as a risk factor for MRSA acquisition (Schneider-Lindner, Delaney et al. 
2007; Dancer 2009; Tattevin, Basuino et al. 2009).  The fluoroquinolones have also been shown 
to up-regulate the expression of adhesion proteins potentiating virulence, indicating that selection 
of MRSA is more complicated than simply advantaging a resistant population (Dancer 2008). 
 Macrolides and lincosamides have also historically been important in the treatment of S. 
aureus and S. pseudintermedius infections in people and dogs (Littlewood, Lakhani et al. 1999; 




increasing and in the case of clindamycin, can be much more insidious.  Macrolide/lincosamide 
resistance is not uniformly expressed in S. aureus and S. pseudintermedius and in vitro 
susceptibility test results may not be predictive of genotype or in vivo resistance expression 
(CLSI 2008; Rubin, Ball et al. 2011).  Inducible clindamcyin resistance (iCR) is a phenomenon 
where the weak resistance inducing power of clindamycin results in an isolate appearing 
susceptible in vitro despite possessing the requisite resistance genes (CLSI 2008).  Clinically, in 
vivo induction of resistance by clindamycin has led to treatment failure, highlighting the 
importance of iCR (Levin, Suh et al. 2005).  In erythromycin resistant, clindamycin susceptible 
isolates, iCR can be confirmed using the “D-test” (CLSI 2008).  In the D-test, erythromycin and 
clindamycin discs are placed 15 mm apart under standard antimicrobial susceptibility testing 
conditions (CLSI 2008).  Blunting of the clindamycin inhibitory zone such that it resembles a 
“D” indicates induction of clindamycin resistance by erythromycin, confirming iCR (Figure 1.1) 
(CLSI 2008).  Inducible clindamcyin resistance seems to be more common among S. aureus than 
S. pseudintermedius.  One study found iCR in 17.7% of canine MRSA and 0% of MRSP, while 
another found it in only 1.7% of canine methicillin susceptible S. pseudintermedius (Faires, Gard 
et al. 2009; Rubin, Ball et al. 2011).  Inducible clindamcyin resistance has been found in both 
MSSA (14.8% – 68%) and MRSA (4.8-24.4%) isolated from human beings (Levin, Suh et al. 
2005; Yilmaz, Aydin et al. 2007).   
 Mupirocin, a pseudomonic acid antimicrobial, is topically applied for treating superficial, 
localized infections and for nasal decolonization (Bryskier 2005; McConeghy, Mikolich et al. 
2009).  Compared to other antimicrobials, relatively little is known about the prevalence of 
mupirocin resistance.  Additionally standardized methods for measuring and interpreting 




Saskatchewan, previous studies have documented higher rates of mupirocin resistance (>50%) 
than elsewhere in Canada (4-7%) (Mulvey, MacDougall et al. 2005; Simor, Stuart et al. 2007). 
Whether the high prevalence of resistance is due to unusually high mupirocin use in this area, or 
some other factor is unknown.   Mupirocin resistance is uncommon among canine isolates, one 
study including S. aureus and S. pseudintermedius found only a single mupirocin resistant 
MRSA, while another examining only MRSA found no mupirocin resistance (Fulham, Lemarie 
et al. 2010; Coelho, Torres et al. 2011). 
 Resistance to other classes of antimicrobials including the aminoglycosides, sulfonamides 
and tetracyclines further complicates the treatment of MRSA infections (Wulf and Voss 2008; 
Enoch, Karas et al. 2009). The increasing incidence of infections caused by multidrug resistant 
Gram-positive organisms (MRSA and VRE) has led to intensive drug discovery/development 
research which, unlike the case with Gram-negatives, has yielded several new antimicrobial 
classes (Loeffler, Linek et al. 2007; Livermore 2009).  Fortunately, pan-resistant isolates are still 
uncommon, but the trend of increasing resistance foreshadows a future resembling the “pre-
antibiotic era” (Arias and Murray 2009; Livermore 2009). 
 Linezolid, the first drug in the newly developed oxazolidinone class, is the first new 
antimicrobial class introduced since the fluoroquinolones in the 1980s (Fernandes 2006; 
Woodford and Livermore 2009).  Unfortunately, linezolid resistance is already emerging, and 
although more common among coagulase negative staphylococci, linezolid resistant S. aureus 
has also been reported (Anderegg, Sader et al. 2005; Woodford 2005; Trevino, Martinez-Lamas 
et al. 2008).  Daptomycin, a lipopeptide antimicrobial, was added to our antimicrobial 
armamentarium in 2003.  It has proven useful in treating refractory infections, although few 





Figure 1.1 Inducible clindamycin resistance  
Staphylococcus aureus displaying typical “D-zone” of inhibition associated with inducible clindamycin resistance 









agents including quinupristin/dalfopristin (streptogramins) and tigecycline (glycylcycline) have 
also been recently become available (Livermore 2009).  These drugs are derivatives of existing 
compounds and resistance may therefore be quicker to develop than to a drug with a novel 
mechanism of action (Giguere 2006; Woodford and Livermore 2009).  Currently, novel PBP2a 
binding cephalosporins (ceftobiprole and ceftaroline), folate synthesis inhibitors (icalprim), 
glycopeptide derivatives (dalbavancin, telavancin and oritavancin) and carbapenems 
(razopenem) are under investigation (Bogdanovich, Ednie et al. 2005; Scheinfeld 2007; Peppard 
and Schuenke 2008; Livermore 2009).  While the drugs currently in the development pipeline for 
Gram-positive bacteria are more promising than for Gram-negatives, the emergence of resistance 
will no doubt continue to challenge the treatment of these infections (Fischbach and Walsh 2009; 
Livermore 2009). 
1.2.5 The implications of MRSA 
1.2.5.1 Increased financial burden and mortality rate 
 The incidence of systemic S. aureus infection (sepsis) has been increasing compared to 
Gram-negative infections, and MRSA is comprising an increasing proportion of these S. aureus 
infections (Klein, Smith et al. 2007; Hodgin and Moss 2008; Laupland, Ross et al. 2008; Simor, 
Gilbert et al. 2010).  The healthcare costs associated with septicemia are immense since these 
patients require intensive monitoring, intravenous access and often the administration of multiple 
drugs or other medical products such as plasma.  In addition, the costs of supplies, facilities and 
staff increase with each day of admission.  The costs of managing MRSA bloodstream and other 
nosocomial infections are up to three times higher than those for MSSA infections (Abramson 
and Sexton 1999; Ott, Bange et al. 2010).  The length of hospitalization is a contributing factor: 




with MSSA septicemia (Abramson and Sexton 1999).  While the financial burden of MRSA is 
obvious, the increased mortality rate associated with MRSA vs. MSSA septicemia or pneumonia 
clearly illustrates the human costs (Laupland, Ross et al. 2008; Ott, Bange et al. 2010).  Hospital 
acquired infections (which are increasingly caused by MRSA) affect 1/9 patients and result in the 
deaths of 8,000 people annually in Canada (Backman, Zoutman et al. 2008; Simor, Gilbert et al. 
2010). 
 
1.2.5.2 Lack of information for dogs 
 In contrast to people, relatively little is known about the implications of MRSA for 
canine health or the costs of treatment.  In dogs, MRSA infections most frequently present as 
pyoderma or otitis externa (Faires, Traverse et al. 2010).  Perhaps due to the superficial nature of 
canine MRSA  infections, or the small number of published cases available for analysis, Faires et 
al., did not find a difference in mortality or the requirement for surgery for dogs infected with 
MRSA versus MSSA (Faires, Traverse et al. 2010).  Few studies have examined the incidence of 
canine MRSA infections, however one study found that 22-36% of clinical S. aureus isolates 
from dogs were methicillin resistant (Jones, Kania et al. 2007).  Among clinically healthy dogs in 
the community, or upon entering veterinary clinics, between 0-1% of dogs were MRSA 
colonized, while 9% of hospitalized dogs were reported to carry MRSA (Loeffler, Boag et al. 
2005; Boost, O'Donoghue M et al. 2007; Hanselman, Kruth et al. 2007; Murphy, Reid-Smith et 
al. 2009). 
 
1.2.6 The situation in Saskatoon, Canada 




 The epidemiology and incidence of MRSA is relatively ill defined in North America 
compared to the Netherlands and Denmark (Larsen, Stegger et al. 2007; van Rijen, Van Keulen 
et al. 2008; Nulens, Stobberingh et al. 2009; Hasman, Moodley et al. 2010; Simor, Gilbert et al. 
2010).  In Canada, current antimicrobial resistance surveillance programs including MRSA are 
targeted at specific patient populations, and may not be representative of S. aureus infections in 
the general public (Canada 2008; Zhanel, Decorby et al. 2008).  Further confounding our 
understanding of MRSA in Saskatoon is the way in which resistance surveillance data is 
presented; the Canadian Nosocomial Infection Surveillance Program combines Saskatchewan 
data with the rest of western Canada (British Columbia, Alberta and Manitoba) (Canada 2008).   
 
1.2.6.2 In dogs 
 Because very little attention was paid to S. aureus in dogs in Saskatoon before 2006 when 
the first canine case of MRSA was recognized, it is difficult to speculate how its epidemiology 
has changed.  Although canine S. aureus infections have only recently gained attention, its true 
importance may have been underestimated in the past.  Misidentification of S. aureus due 
clinical bias and morphological similarities with S. pseudintermedius should not be discounted.  
At the WCVM there have been relatively few (nine) canine MRSA infections associated with 
three outbreaks in 2006 and 2008 (Rubin and Chirino-Trejo In Press).  Outside of Ontario, where 
a number of outbreaks have been reported, there is no other published data on canine MRSA in 
Canada (Weese, Dick et al. 2006; Weese, Faires et al. 2007).   
 
1.2.7 Control strategies 




 In human beings, decolonization of the anterior nares to eliminate MRSA is commonly 
done prophylacticly before high risk medical procedures (McConeghy, Mikolich et al. 2009).  
Topically applied mupirocin is the most commonly used drug, and the only licensed product for 
nasal decolonization (McConeghy, Mikolich et al. 2009).  Resistance to mupirocin necessitates 
the use of other drugs; fusidic acid as well as topically applied vancomycin, 
bacitracin/neomycin/polymyxin B and chlorhexidine gel have also been used (Manian 2003; 
McConeghy, Mikolich et al. 2009).  Nasal colonization refractory to topical therapy may require 
systemic treatment for which rifampin and trimethoprim/sulfamethoxazole, clindamycin, 
clarithromycin, fusidic acid, doxycycline or ciprofloxacin have been used (van Duijkeren, 
Wolfhagen et al. 2005; Barton, Hawkes et al. 2006; Wertheim, Nouwen et al. 2007).  
Antimicrobial soaps and bathing solutions including chlorhexidine, triclosan and Dakin’s 
solution (dilute hypochlorite) are also used in parallel with nasal decolonization (Elston 2009; 
McConeghy, Mikolich et al. 2009).  
 With the recognition of multiple sites of colonization, decolonization regimens for extra-
nasal sites are being investigated (Ammerlaan, Kluytmans et al. 2009).  Enteral decolonization 
presents unique challenges since the intestines are not accessible for topical therapy and the 
toxicity of potential decolonization agents must be carefully considered (Batra, Eziefula et al. 
2008; Ammerlaan, Kluytmans et al. 2009).  Some authors have suggested that oral vancomycin, 
due to its poor oral bioavailability, might be an effective agent for enteral decolonization 
although the risk of selecting vancomycin resistant enterococci must be considered (Batra, 
Eziefula et al. 2008; Huckabee, Huskins et al. 2009).  
 Pharmacologic decolonization of dogs is a controversial issue and there is no data to 




anterior nares, and it seems reasonable to assume that effective mupirocin concentrations would 
be quickly obliterated by licking and sneezing (Batra, Eziefula et al. 2008; Weese and van 
Duijkeren 2010).  Successful decolonization of a dog using intranasal vancomycin ointment, or 
systemic ciprofloxacin + rifampin has been reported (Manian 2003; van Duijkeren, Wolfhagen et 
al. 2005).  Unfortunately the drugs in these regemins may be associated with serious adverse 
effects (rifampin induced hepatitis) or uncertain and potentially serious resistance implications 
(vancomycin) (Dowling 2006; Weese 2008).  Furthermore, the efficacy of canine decolonization 
regimens has not been investigated and prospective studies are required before evidence based 
interventions can be implemented.  Currently, experts in the field have suggested that most dogs 
spontaneously decolonize and that pharmacological interventions are unlikely to be successful 
(Barton, Hawkes et al. 2006; Weese and van Duijkeren 2010). 
 
1.2.7.2 Search and destroy – control in the population 
 Unlike other countries, the Netherlands has been very successful in minimizing the 
incidence of MRSA infection (Wertheim, Vos et al. 2004).  The Dutch success story can be 
largely attributed to the national “search and destroy” strategy.  Search and destroy encompasses 
four main components: 1. Isolating high risk individuals with known risk factors on admission to 
hospital, 2. Screening hospital patients for MRSA colonization, 3. Decolonization, 4. Molecular 
characterization of positive cultures (Infection.Prevention.Working.Party 2011).   
 In the Netherlands, previous MRSA diagnosis, working or living with pigs or veal calves 
and foreign hospitalization are considered important risk factors under search and destroy.  High-
risk individuals are physically isolated within the hospital including personal protective 




patients and the general hospital population.  All MRSA positive individuals are decolonized 
(Infection.Prevention.Working.Party 2011).  Depending on the clinical situation of the patient 
intra-nasal mupirocin, chlorhexidine soap for showering and frequent changing of towels and 
bed linens and daily underwear changes are prescribed (Wertheim, Nouwen et al. 2007).  For 
complicated cases, systemic therapy may also be required (Wertheim, Nouwen et al. 2007).  
 Molecular epidemiological surveillance is a key component of the Dutch strategy.  The 
first MRSA isolate from each patient is typed at the Dutch national lab (RIVM) (Wertheim, 
Nouwen et al. 2007; Infection.Prevention.Working.Party 2011).  The characterization of isolates 
allows them to be compared to a database, facilitating detection of outbreaks and newly 
emerging strains.   
 There are high up front costs associated with search and destroy, however the prevention 
of MRSA infections has been demonstrated to result in overall savings (Vriens, Blok et al. 2002).  
In one hospital the annual cost of search and destroy was calculated to be €215,559 while the 
healthcare savings were estimated to be €427,356 (van Rijen and Kluytmans 2009).  The vast 
resources needed for search and destroy limit its application to regions with a low incidence of 
MRSA. The strict MRSA policies in the Netherlands have resulted in one of the lowest 
incidences of MRSA infections in the world <1% of S. aureus bacteremia caused by MRSA 
compared to 50% in other areas of Europe (Kluytmans and Struelens 2009; van Rijen and 
Kluytmans 2009).  In Canada, 24.4% of S. aureus bloodstream infections are caused by MRSA, 
while methicillin resistance is found in 19-54.8% of community associated S. aureus infections 






1.3 Staphylococcus pseudintermedius 
1.3.1 Colonization  
 In dogs, S. pseudintermedius is the most commonly encountered coagulase positive 
staphylococcal species, as both a colonizer and cause of infections (Ball, Rubin et al. 2008; 
Griffeth, Morris et al. 2008).  The prevalence of S. pseudintermedius colonization in dogs is ill 
defined.  Staphylococcus pseudintermedius has been found in 58.5-81% of dogs with otitis and 
pyoderma, and up to 68% of healthy dogs although few studies have been done (Lyskova, 
Vydrzalova et al. 2007; Griffeth, Morris et al. 2008).  Colonization studies have examined 
different body sites including the nares, pharynx, gastrointestinal tract, axilla and skin although a 
systematic comparison of these sites has not been done (Hanselman, Kruth et al. 2007; Griffeth, 
Morris et al. 2008).  Knowledge of colonization sites will allow future investigations to achieve 
maximal screening sensitivity while avoiding sites of little diagnostic value. 
 
1.3.2 Staphylococcus pseudintermedius as a Canine Pathogen 
 Staphylococcus pseudintermedius is commonly implicated in canine infections, 
accounting for the majority of otitis externa and pyoderma isolates, and 16.5% of urinary tract 
infection isolates (Werckenthin, Cardoso et al. 2001; Ball, Rubin et al. 2008).  Like S. aureus, S. 
pseudintermedius is an opportunistic pathogen causing infections when host defenses are 
compromised (Weese and van Duijkeren 2010).  
 
1.3.3 Antimicrobial resistance among S. pseudintermedius 
 In Saskatoon, S. pseudintermedius has historically remained remarkably susceptible to 




pseudintermedius infections have been successfully treated with first-line drugs including the 
amino-penicillins and first generation cephalosporins (amoxicillin, cephalexin).  For infections 
requiring a drug with increased tissue penetration, such as osteomyelitis and deep pyoderma, 
clindamycin has been the treatment of choice (Littlewood, Lakhani et al. 1999; Giguere 2006).  
Clinical S. pseudintermedius cultures isolated between 1986 and 2000 at the Western College of 
Veterinary Medicine were reported to be overwhelmingly susceptible; resistance to penicillin 
was found in only 7% of isolates, erythromycin in 13% and tetracycline in 34% and no 
methicillin resistance was found (Rubin, Ball et al. 2011).   
 The incidence of methicillin resistant S. pseudintermedius (MRSP) is increasing rapidly, 
challenging clinicians in treating their patients (Epstein, Yam et al. 2009; Ruscher, Lubke-
Becker et al. 2010).  While the only MRSP reports in Canada originate in Ontario and 
Saskatchewan, anecdotally it has also occurred in at least Alberta and British Columbia 
(Hanselman, Kruth et al. 2007; Rubin and Gaunt 2011).  In 2009, the first canine MRSP 
recognized at the WCVM was isolated from a urinary tract infection (Rubin and Gaunt 2011).  In 
stark contrast to the S. pseudintermedius typically encountered in Saskatoon, this isolate was 
resistant to the β-lactams, fluoroquinolones, macrolides, aminoglycosides, sulfonamides, 
chloramphenicol and rifampin (Rubin and Gaunt 2011).  This urinary tract infection was 
community associated: no identifiable risk factors for a multidrug resistant organism were 
identified (Rubin and Gaunt 2011).  The explosive increases in MRSP prevalence in Europe and 
North America are further complicated by multidrug resistance, which in contrast to CA-MRSA 
is common among MRSP (Wettstein, Descloux et al. 2008; Ruscher, Lubke-Becker et al. 2010; 





1.4 Antimicrobial susceptibility testing 
 Whether done to direct therapy or for resistance surveillance, antimicrobial susceptibility 
testing requires stringent quality control and standardized methods to yield valid results.  
Standard methods of dilutional susceptibility testing (broth and agar), disc diffusion and 
epsilometer testing have been developed (CLSI 2006; CLSI 2006; Biomerieux 2008).  These 
guidelines describe all aspects of the testing procedure including media specifications, bacterial 
inoculum, solvents and diluents for each antimicrobial, incubation time and temperature and 
interpretive criteria for categorical analyses (CLSI 2006; CLSI 2006; CLSI 2008; CLSI 2008).   
 The validity of results can be objectively evaluated by testing quality control organisms 
along with the isolates under investigation; these QC organisms have defined susceptibility 
profiles allowing comparison to published QC ranges (CLSI 2008).  The selection of QC 
organisms should be based on the drugs tested and each drug should have a corresponding 
organism with a QC range including the concentrations tested.  Commonly used QC organisms 
for testing non-fastidious aerobic bacteria include S. aureus ATCC 25923, S. aureus ATCC 
29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922 and Pseudomonas 
aeruginosa ATCC 27853 (CLSI 2008). 
 While it is always tempting to classify an isolate as susceptible or resistant, this 
classification must be avoided for drugs without recognized interpretive criteria.  Resistance 
breakpoints are designed to be clinically predictive and are established based on the intended use 
of the drug  (licensed indication), dosing regimen (dose, route and frequency), pharmacokinetic 
properties of the drug in the host species and the pharmacodynamic interactions between the 
organism and the drug (Walker 2006; Andrews 2008; Dalhoff, Ambrose et al. 2009).  Valid 




other national and international standards organizations’ but these criteria are only valid when 
testing is done according to the respective organizations guidelines.  Epidemiological cut-off 
values differentiate organisms with acquired resistance from the wild type and are invaluable for 
detecting the emergence of “resistance” but they must be recognized as distinct from clinical 
breakpoints as they are not designed to be clinically predictive (Dalhoff, Ambrose et al. 2009).   
 
1.5 Molecular epidemiology of S. aureus 
 The epidemiology of S. aureus is complex, with a distinct ecological niche in each host 
species, and geographic variation between the community and health care facilities within a 
region (Wertheim, van Leeuwen et al. 2005; Abbott, Leonard et al. 2010; Grundmann, Aanensen 
et al. 2010; Hasman, Moodley et al. 2010).  This complexity is compounded when distinct S. 
aureus populations meet.  A plethora of molecular tools have been developed for conducting 
evolutionary studies, documenting the population within a single niche or those moving between 
reservoirs and tracking outbreaks. 
 
1.5.1 Techniques 
 There are many techniques available which are variably suited to particular research 
questions, and associated with their own set of technical advantages and disadvantages 
(Savelkoul, Aarts et al. 1999).  The investigator must be aware of a technique’s limitations, 
discriminatory power and reproducibility so that genetic fingerprints can be interpreted in a 
meaningful way; the level of discrimination relevant for the investigation must be considered.   
 When defining isolates as related or indistinguishable using a particular technique, it is 




in the literature and is imprecisely used to refer to a grouping such as a sequence type (MLST), 
pulsotype (PFGE) or isolates which are presumed to be related or “clonal”.  According to 
Webster’s Third New International Dictionary, a strain is “a line descended or derived from a 
particular ancestral individual”, and example would be a type strain such as those catalogued by 
the American Type Culture Collection (ATCC) (Grove 1993).  The application of this definition 
to isolates defined using methods with varying discriminatory power is imprecise, a sequence 
type may not be phylogenitcally equivalent to an MLVA profile.  Ambiguity is also associated 
with the term “clone”, which when discussing S. aureus is often used to describe isolates 
belonging to the same pulsotype, the “USA300 clone” for example (Schwartz, Graber et al. 
2009).  Strictly speaking clones are derived from a common ancestor and are genetically 
identical, the level of similarity attributed to two given isolates is more reflective of the 
discriminatory power of the technique than the true homology of the organisms (Tibayrenc 
2009).   
 The ambiguousness of the widely employed nomenclature used to describe the genetic 
relationships between isolates should be avoided and replaced with precise terminology specific 
to the method used.  For example, instead of referring to to isolates as the “same strain”, it would 
be clearer to say that they are: the same sequence type, spa type, have indistinguishable PFGE 
profiles or the same binary IS profile.  A high degree of precision and accuracy in definitions are 
required to communicate scientific findings in an efficient and useful way.   
 
1.5.1.1 Pulsed-field gel electrophoresis (PFGE) 
 Pulsed field gel electrophoresis (PFGE), a technique popularized by the US Centers for 




bacteria, has been considered the gold standard technique for discriminating bacterial strains of 
many clinically relevant species (Mulvey, Chui et al. 2001; CDC 2011).  In PFGE, whole 
genomic DNA is digested using a restriction enzyme, the resulting fragments are then resolved 
on a gel in a specialized apparatus and banding patterns are analyzed (CDC 2011).  In addition to 
being technically demanding and time consuming, it has been difficult to achieve a high degree 
of inter-laboratory reproducibility despite the development of standardized protocols (Mulvey, 
Chui et al. 2001; Melles, van Leeuwen et al. 2007).   
 The resolving power of PFGE has made it a benchmark for comparison for new 
techniques (Malachowa, Sabat et al. 2005; Petersson, Olsson-Liljequist et al. 2009; Schouls, 
Spalburg et al. 2009).  Until recently, PFGE was the method of choice for reference labs around 
the world and distinct typing nomenclatures were developed in different regions.  Consequently,  
one system may not be uniformly described by another and the same “strain” may have different 
designations in each typing system (Mulvey, Chui et al. 2001; Christianson, Golding et al. 2007; 
Cookson, Robinson et al. 2007; Kim, Ferrato et al. 2010).  In Canada, isolates are designated 
CMRSA 1 – CMRSA 10 (Christianson, Golding et al. 2007).  The technical demands of PFGE 
combined with the decreasing costs of sequencing and the need for globally comparable data is 
giving rise to a new generation of sequence and PCR based techniques. 
 
1.5.1.2 Multilocus sequence typing (MLST) 
 As a relatively low-resolution, high-fidelity technique, MLST is best suited to big picture 
evolutionary studies (Maiden, Bygraves et al. 1998; Robinson and Enright 2004; Aanensen and 
Spratt 2005; Melles, van Leeuwen et al. 2007; Palavecino 2007; Turner and Feil 2007).  The 




(Aanensen and Spratt 2005).  MLST is based on the sequences of seven housekeeping genes 
(arcC, aroE, glpF, gmk, pta, tpi and yqiL) (Enright, Day et al. 2000).  Each unique sequence for 
each gene is assigned a number in the MLST database and the numeric profile from all seven 
genes defines the sequence type (Enright, Day et al. 2000).  Unique sequence types are also 
assigned numerical identities in the database.  New sequence types are numbered sequentially as 
they are describeded.  The relatedness of ST97 and ST98 for example must be based on the 
seven gene numeric profile 3-1-1-1-1-5-3 and  1-4-1-35-12-1-10 respectively, rather than the 
sequence type number itself (Aanensen 2011).  While MLST won’t detect divergence among 
closely related S. aureus lineages, it is valuable for evolutionary studies and for broadly 
clustering the finely resolved types identified with other techniques. 
 
1.5.1.3 spa typing  
 Sequencing the hyper-variable x-region of the staphylococcal protein A (spa) gene is 
another objective, sequenced based molecular tool for characterizing S. aureus (Harmsen, Claus 
et al. 2003).  Unlike MLST, spa typing discriminates between closely related isolates; its 
resolving power is somewhere between PFGE and MLST (Harmsen, Claus et al. 2003; Hallin, 
Friedrich et al. 2009; Petersson, Olsson-Liljequist et al. 2009).  Within a sequence type there 
may be many spa types (SpaServer 2011).  Like MLST, spa types are cataloged in a central, 
web-based database allowing easy access to the details of each spa type and global 
epidemiological information (Harmsen, Claus et al. 2003).  As an objective fast and inexpensive 
technique, spa typing is quickly gaining favour, and it is now routinely used in diagnostic, 
reference and research labs around the world.  The hyper-variable x-region contains a variable 




Presently , 462 unique, short sequences termed “repeats” have been described and assigned a 
numerical identifier (SpaServer 2011).  For example the 24 base pair sequence 5’ AAA GAA 
GAC AAC AAA AAA CCT GGT-3’ was the thirty fourth repeat deposited in the database and is 
therefore identified as “r34” (SpaServer 2011).  An isolate is assigned a spa type according to 
which and how many repeats are present (2-16) and their order (Hallin, Friedrich et al. 2009).  
spa types are identified numerically in the order of their discovery.  Because spa types are 
numbered in the order of their discovery no genetic relationship can be inferred from 
sequentially numbered types; relatedness is dictated by the repeat sequence of each type.  For 
example t034 (r08-r16-r02-r25-r02-r25-r34-r24-r25) is more closely related to t4652 (r08-r16-
r02-r25-r02-r25-r34-r24) than t035 (r26-r17-r13-r12-r17-r17-r16) (SpaServer 2011). 
 
1.5.1.4 Amplified fragment length polymorphism (AFLP) 
 Like PFGE, AFLP is a band-based technique which detects polymorphisms throughout 
the whole genome (Savelkoul, Aarts et al. 1999; Melles, Gorkink et al. 2004; Fry, Savelkoul et 
al. 2009).  In AFLP, genomic DNA is digested using restriction enzymes, site specific adaptors 
are then ligated to restriction fragments, fragments are amplified by PCR and the amplicons are 
resolved by electrophoresis (Fry, Savelkoul et al. 2009).  The resolving power of AFLP is similar 
to PFGE, allowing discrimination of closely related isolates without some of the technical 
challenges associated with PFGE (Melles, van Leeuwen et al. 2007).  Despite its advantages, 
AFLP suffers from a number of disadvantages including a lack of inter-laboratory 
standardization and the development of more objective, sequence based techniques (Melles, van 





1.5.1.5 16S – 23S interspace typing (IS-typing) 
 Although the costs of sequencing are rapidly decreasing, the simplicity and objectivity of 
PCR based techniques has led to the development of IS-typing techniques.  There are five or six 
copies of the 16S-23S interspace region in the S. aureus chromosome (Budding, Vandenbroucke-
Grauls et al. 2010).  The length of this region varies within and between individual isolates 
(Budding, Vandenbroucke-Grauls et al. 2010).  While the length of this region is variable, this 
variation is limited to combinations of 16 defined region lengths (Budding, Vandenbroucke-
Grauls et al. 2010).  The IS-type is based on a binary profile of the isolates resulting from the 
presence of absence of each of the 16 defined region lengths (Budding, Vandenbroucke-Grauls et 
al. 2010).  Resolution of amplicons on either agarose slab gels or high resolution capillary gels 
allows easy application of this technique in labs with only basic equipment (Budding, 
Vandenbroucke-Grauls et al. 2010).  The discriminatory power of IS-typing is similar to MLST 
and a previous study demonstrated good agreement between these two techniques (Budding, 
Vandenbroucke-Grauls et al. 2010). 
 
1.5.1.6 Multiple locus variable number tandem repeat analysis (MLVA) 
 Multiple locus variable number tandem repeat (VNTR) analysis (MLVA) is a new, very 
high resolution technique for differentiating closely related S. aureus isolates (Moser, Box et al. 
2009; Schouls, Spalburg et al. 2009).  A VNTR locus is one where a defined DNA sequence, 
between 9 – 560 base pairs for S. aureus depending on the loci used, repeats a variable number 
of times (Vergnaud and Pourcel 2009).  Variation between isolates in the number of repeats at a 
given locus is the basis of the technique.  Like IS-typing, MLVA is a PCR based technique 




(Malachowa, Sabat et al. 2005; Vergnaud and Pourcel 2009).  The number of repeats determines 
the length of the locus and this length may vary diagnostically between individual isolates 
(Ikawaty, Willems et al. 2008; Vergnaud and Pourcel 2009).  For typing, the repeat length at a 
given VNTR locus must first be determined using DNA sequencing, or by using a previously 
published method.  Products from VNTR region PCR are resolved on a gel, and the size of the 
amplion calculated by comparison with a known DNA ladder run in parallel (Vergnaud and 
Pourcel 2009).    The number of repeats is then calculated using the following equation: 
 
 
n = (a – c) / r 
 
Where: n = number of repeats 
  c = product constant of the locus 
  a = amplicon length  




The product constant “c” must be included to correct for non-repeat regions flanking the VNTR 
in the amplified product including primer binding sites (Vergnaud and Pourcel 2009) 
 When multiple VNTR loci are combined, the number of repeats at each locus are 
combined yielding a string of numbers which defines the strain (Schouls, Spalburg et al. 2009). 
 The hyper-variability of some VNTR loci allows changes in closely related isolates to be 
detected (Ikawaty, Willems et al. 2008).  There is concern that MLVA may actually be too 
discriminatory, detecting temporal drift between clonal isolates highlighting differences not 
reflective of epidemiological relationships (Tanner, Hardy et al. 2010).  In the future, MLVA 
with carefully calibrated cut offs used to differentiate isolates (or identify them as 
indistinguishable), may prove to be a highly valuable, high resolution, inexpensive, objective and 




1.5.2 MRSA “strains” of particular interest 
 The dissemination of MRSA from the hospital into the community has, since the late 
1990s, been associated with the emergence of a number of MRSA lineages (Oliveira, Tomasz et 
al. 2002; Adam, Allen et al. 2009; Chambers and Deleo 2009; Li, Diep et al. 2009).  
 In Canada there has been a 17-fold increase in the incidence of CA-MRSA infection 
since the mid 1990s, although this increase has not been geographically uniform in magnitude or 
“strain” type (Simor, Gilbert et al. 2010). In 2004, the first outbreak of USA 300 (CMRSA10) 
was recognized in Calgary, Alberta (Gilbert, MacDonald et al. 2006; Christianson, Golding et al. 
2007).  Between 2005 and 2008 the incidence of MRSA infection in Alberta nearly doubled and 
much of this increase was attributed to the rise of USA 300 (CMRSA10) which by 2008 
comprised 53% of MRSA isolates (Christianson, Golding et al. 2007; Kim, Ferrato et al. 2010).  
In contrast, the USA 400 (CMRSA7) lineage predominates in Manitoba, northern Saskatchewan 
and Nunavut (Christianson, Golding et al. 2007; Simor, Gilbert et al. 2010).  The most prevalent 
lineages in Saskatoon are unknown since recent, locally specific reports have not been published.  
However CMRSA10 is thought to be spreading rapidly and is likely increasing in Saskatchewan 
(Simor, Gilbert et al. 2010). 
 MRSA ST398 was first identified in the Netherlands in 2004 and was initially identified 
as non-typable by PFGE (Voss, Loeffen et al. 2005).  This strain was first isolated from a girl 
with an “unexpected” MRSA infection (no defined risk factors) in July 2004 (Voss, Loeffen et 
al. 2005).  Epidemiological trace-backs found that MRSA ST398 was highly significantly 
associated with livestock; Dutch residents in contact with pigs and veal calves are up to 1,000 
times as likely as the general population to be colonized with MRSA (van Rijen, Van Keulen et 




on 11-70% of pig farms, in 11-49% of pigs on those farms and 20-45% of those working with 
them (Smith, Male et al. 2008; van Duijkeren, Ikawaty et al. 2008; Wulf and Voss 2008; Kock, 
Harlizius et al. 2009).   
 Diversity within the ST398 lineage, multiple spa types and heterogeneous PFGE profiles, 
indicates that different MRSA ST398 isolates may occupy unique epidemiological (host, farm or 
geographical) niches (Bosch, de Neeling et al. 2010; Fessler, Scott et al. 2010).  On closer 
inspection, diversity in the resistance gene and virulence factor profile, and SCCmec types have 
also been reported among MRSA ST398 isolates (Laurent, Jouy et al. 2009; Skov, Li et al. 2009; 
Stegger, Lindsay et al. 2009). 
 In pigs, MSSA ST398 is common, and it is thought that acquisition of mecA by members 
of this already successful lineage may be responsible for the rise of livestock associated MRSA 
(Hasman, Moodley et al. 2010).  There has been a lot of speculation regarding potential factors 
that could have selected for MRSA ST398 in pigs, particularly antimicrobial usage, however 
solid evidence has not been published (Wulf and Voss 2008).  Authors of early reports 
hypothesized that the high frequency of tetracycline resistance among MRSA ST398 suggested 
that tetracycline use could select for this strain (Wulf and Voss 2008).  However, these 
investigators failed to recognize that tetracycline resistance is common among porcine MSSA, 
and that tetracycline usage would therefore not likely select for MRSA over MSSA (Hasman, 
Moodley et al. 2010; Rubin, Ball et al. 2011).   
 Recently evidence implicating tiamulin, a pleuromutilin antimicrobial used exclusively in 
animal agriculture, as a potential selection pressure for MRSA ST398 was published (Rubin, 
Ball et al. In Press).  Retapamulin, the only pleuromutilin antimicrobial available for human use, 




several years after the emergence of MRSA ST398 and several decades after the introduction of 
tiamulin  (FDA 1987; Daum, Kar et al. 2007).  MRSA ST398 were reported to have tiamulin 
MICs significantly higher than human MSSA and non-ST398 MRSA isolates and porcine MSSA 
(Rubin, Ball et al. In Press).  While further study is required, these data suggest that the use of 
tiamulin in pigs may impart a potent selective pressure in favour of MRSA ST398. 
 
1.6 Interspecies transmission 
1.6.1 S. aureus 
 Staphylococcus aureus is a promiscuous colonizer/cause of infections, which has been 
identified in many species (Weese and van Duijkeren 2010).  While some S. aureus lineages tend 
to be species-specific only occasionally venturing into different hosts, others have little regard 
for such barriers (Sung, Lloyd et al. 2008; Weese and van Duijkeren 2010).  For example S. 
aureus ST5 is an internationally prevalent lineage that crossed from people into chickens in the 
mid 1900s while CMRSA5 is a lineage disproportionally associated with horses and people with 
equine contact (Weese, Archambault et al. 2005; Lowder, Guinane et al. 2009; Abbott, Leonard 
et al. 2010; Weese 2010).  In contrast to ST5, S. aureus isolated from bovine mastitis are 
genetically distinct from human isolates, indicating that transmission in either direction is 
infrequent (Smyth, Feil et al. 2009) 
 
1.6.1.1 Dogs and people 
 With the emergence of MRSA in dogs, more attention has been paid to canine S. aureus 
infections and the origin of these organisms.  As S. pseudintermedius colonization predominates 




in close contact with the dogs (Weese and van Duijkeren 2010).  The complex ecology of S. 
aureus including canine-human transmission dynamics, remains ill defined.  Although 
transmission has been documented, and there is evidence of a shared S. aureus population, these 
interactions have not been adequately defined (Simoons-Smit, Savelkoul et al. 2000; Manian 
2003). 
 In one report, a diabetic man with a non-healing wound infected with MRSA was 
unsuccessfully treated (Manian 2003).  Repeated treatment and decolonization attempts were 
made.  His wife was also colonized, although decolonization attempts of both failed to eradicate 
MRSA from the household.  Eventually the couple’s dog was sampled and found to be 
colonized.  A decolonization regimen for the dog (intra-nasal vancomycin ointment) was 
administered and the man’s infection was finally cleared (Manian 2003). 
 Transmission in veterinary hospitals is also recognized, and companion animal 
veterinarians (small animal and equine) are known to be at elevated risk of colonization 
(Hanselman, Kruth et al. 2006; Loeffler, Pfeiffer et al. 2010).  Bidirectional transmission 
between companion animals (cats and dogs) and humans including veterinary staff has been 
described (Weese, Dick et al. 2006). 
 
1.6.1.2 MRSA ST398 (livestock associated MRSA) 
 While MRSA ST398 has been reported in association with horses, chickens and dogs, 
swine contact is the most important risk factor for human colonization/infection (van Belkum, 
Melles et al. 2008; Kock, Harlizius et al. 2009; Nienhoff, Kadlec et al. 2009; Tokateloff, 
Manning et al. 2009; Mulders, Haenen et al. 2010; Weese and van Duijkeren 2010).  However, 




risk (van Rijen, Van Keulen et al. 2008; Cuny, Nathaus et al. 2009).  Human to human 
transmission is rare even in the hospital environment; non-ST398 were recently shown to 
transmit 5.9 times as efficiently as ST398 between patients (Bootsma, Wassenberg et al. 2010).   
 
1.6.2 S. pseudintermedius  
 In contrast to S. aureus, S. pseudintermedius is the most common coagulase positive 
staphylococcal species in dogs and is infrequently identified from people (Griffeth, Morris et al. 
2008; Kempker, Mangalat et al. 2009).  Like S. aureus in dogs, S. pseudintermedius may be 
under-recognized as a cause of human infections (Pottumarthy, Schapiro et al. 2004; van 
Duijkeren, Ikawaty et al. 2008).  Depending on the methods used to identify S. aureus, S. 
pseudintermedius could easily be mistaken for S. aureus (van Duijkeren, Ikawaty et al. 2008).  In 
human beings, S. pseudintermedius has been most commonly identified from canine bite 
wounds, a situation where canine flora would be expected, although transmission without 
traumatic contact has also been reported (Talan, Staatz et al. 1989).  Among the small number of 
reported cases of human S. pseudintermedius infection, one was a patient who had undergone 
surgery for a pituitary neoplasia who subsequently developed a pituitary abscess (Tanner, Everett 
et al. 2000; van Duijkeren, Houwers et al. 2008; Kempker, Mangalat et al. 2009).  A recent study 
provided indirect evidence of zoonotic S. pseudintermedius transmission by demonstrating 
MRSP colonization of veterinarians (Paul, Moodley et al. In Press).  Similarly, transmission 







Chapter 2 - Hypotheses, Rationale and Objectives 
 
2.1 Hypotheses 
The ability of S. aureus isolated from different species to coagulate canine vs. rabbit plasma will 
vary, and that canine S. aureus will coagulate canine plasma faster than rabbit plasma. 
 
Dogs are nasally, pharyngeally and rectally colonized with S. aureus and S. pseudintermedius 
including individuals that are single site colonized. 
 
Resistance to commonly used antimicrobials in canine medicine will be found among S. 
pseudintermedius isolated from healthy dogs in Saskatoon, Canada. 
 
Resistance to commonly used antimicrobials in canine and human medicine will be found among 
S. aureus isolated from healthy dogs, clinical canine MRSA isolates and clinical S. aureus 
isolated from people in Saskatoon, Canada. 
 











 In the clinical microbiological laboratory, rapid and sensitive tests are desirable for 
identifying organisms causing infections.  The identification of S. aureus in dogs has clinical (for 
the individual patient) and infection control (for other patients, staff and owners) implications.  
As the coagulase test is integral to the identification of S. aureus, a test which rapidly yields 
highly sensitive and specific results is desirable.  The utility of different plasmas for isolates of 
varying origin should therefore be assessed since previous studies have reported that some 
plasmas are coagulated faster than others. 
 Recent investigations in human clinical microbiology have revealed that multiple sites of 
colonization play a role in the ecology of S. aureus in humans.   In dogs, the sites of colonization 
have been largely undefined.  For studies defining the prevalence of S. aureus as well as for 
investigating outbreaks, maximal screening sensitivity (without excessive sampling), necessitates 
knowledge of sites of colonization. 
 The antimicrobial susceptibility profiles of S. pseudintermedius vary geographically.  As 
canine S. pseudintermedius infections are often treated empirically, local definition of 
antibiograms is required to guide therapy.  Additionally, local resistance surveillance is required 
to detect changes in antimicrobial susceptibility.  The antimicrobial susceptibility profiles of S. 
aureus also vary geographically therefore local resistance surveillance is required to detect 
changes in antimicrobial susceptibility. 
 The current literature suggests that people and dogs share a common population of S. 
aureus, and that bidirectional transmission occurs.  Most reports describe outbreak situations (in 
veterinary hospitals) or specific instances of transmission (in an individual household).  Very few 




origin.  To better define the ecology of S. aureus as it relates to people and dogs, the relatedness 

























2.3 Objectives  
Compare rabbit plasma (the current standard) to canine plasma in the tube coagulase test for 
canine, human and bovine S. aureus isolates. 
 
Sample the nares, pharynx and rectum of healthy dogs and determine the prevalence of S. aureus 
and S. pseudintermedius colonization at each site.  In addition to defining the sites of 
colonization overall, the sites colonized in an individual dog will be recorded, including single 
site colonization. 
 
Test the antimicrobial susceptibility of S. pseudintermedius isolated from healthy colonized dogs 
to an extensive panel of antimicrobials. Compounds used systemically in both human and 
veterinary medicine will be evaluated as well and the topical agents mupirocin and fusidic acid. 
 
Test the antimicrobial susceptibility of clinical MRSA isolated from dogs at the WCVM, S. 
aureus isolated from healthy colonized dogs and clinical MRSA and MSSA isolated from people 
in Saskatoon, Canada to an extensive panel of antimicrobials.  Compounds used systemically in 
both human and veterinary medicine will be evaluated as well and the topical agents mupirocin 
and fusidic acid. 
 
Determine the relatedness of canine and human S. aureus using a variety of molecular 



































3.1 Abstract  
 The tube coagulase test, an invaluable laboratory tool for identifying Staphylococcus 
aureus, is most often done using rabbit plasma.  However, there is evidence that depending on 
the origin of the isolates, other plasmas may be superior.  In this study, we sought to compare the 
utility of dog and rabbit plasma in the coagulase test for S. aureus isolated from canine (n=28), 
bovine (n=29), and human (n=30) hosts.  Overall, coagulation times were significantly faster for 
dog (2.38 hours) than rabbit (3.19 hours) plasma.  When coagulation times were compared by 
isolate origin, no significant differences were found for rabbit plasma, whereas bovine isolates 
clotted dog plasma significantly faster (1.86 hours) than canine (2.79 hours) or human (2.38 
hours) isolates.  Investigators should be aware that rabbit plasma may not be the ideal coagulase 
testing medium for S. aureus from all sources.  
 
3.2 The study 
 Staphylococcus aureus is one of the most common causes of infections in people 
worldwide, and is increasingly recognized in companion animals including  dogs (Moet, Jones et 
al. 2007; Weese and van Duijkeren 2010). Recent reports of the increasing prevalence of 
methicillin-resistant Staphylococcus aureus (MRSA) in people and animals have raised 
awareness in the veterinary community about this potential pathogen (Rubin and Chirino-Trejo 
2010; Simor, Gilbert et al. 2010).  S. aureus is identified using a number of standard biochemical 
tests including the tube coagulase test, typically using rabbit plasma (Winn, Allen et al. 2006).   
 Previous studies have documented variability in the coagulability of different plasmas for 
S. aureus isolated from different hosts (Orth, Chugg et al. 1971; Live 1972; Adesiyun and Shehu 




presence of S. aureus biotypes which preferentially clot certain plasmas (Orth, Chugg et al. 
1971; Adesiyun and Shehu 1985).  The importance of identifying S. aureus necessitates sensitive 
and timely coagulase test procedures, particularly in the case of MRSA, where therapeutic and 
infection control measures are markedly different than for susceptible organisms.   The purpose 
of this study was to evaluate the relative utility of dog and rabbit plasmas in the tube coagulase 
test for S. aureus isolated from canine, bovine and human hosts.    
 Eighty seven archived S. aureus isolates were tested.  A total of 30 were of human origin, 
and 29 and 28 were from bovine and canine hosts, respectively.  Commercially prepared rabbit 
plasmaa and dog blood bank plasmab were used. A single well-isolated colony was inoculated 
into 0.5 ml of plasma and incubated at 35°C for 4 hr, followed by room temperature incubation 
(Winn, Allen et al. 2006).  Samples were evaluated hourly unitil clot formation was first detected 
by gently tilting the test tube.   
 Statistical analyses were done using SPSS Version 17.0c.   Dog and rabbit plasma 
coagulase times for all samples were compared using a univariate analysis of variance (ANOVA) 
with Bonferroni correction.  Differences in the time to clot formation for dog and rabbit plasma 
between isolates from each host were compared using one way ANOVAs.  Differences in the 
time to clot formation for dog and rabbit plasma between isolates from the same host species 
were compared using t-tests.  P ≤0.05 was considered significant for all analyses.   
 Overall, the time to clot formation was significantly faster for dog (mean: 2.38 hours) 
than rabbit (mean: 3.19 hours) plasma (P <0.001; Table 3.1).  No significant differences were 
found in time to coagulate rabbit plasma between isolates from different hosts; however, bovine 




= 0.001) or human (2.50 hours, P = 0.029) isolates (Table 3.1).  Bovine and human isolates 




































Canine   Dog†  2.79  2 6
Rabbit  3.07  2 5
Bovine*  Dog†,‡   1.86  1 6
Rabbit   3.38  1 7
Human*  Dog‡  2.38  1 5
Rabbit   3.19  1 7
Overall*  Dog  2.38  1 6
Rabbit   3.19   1 7
 
Significant differences (p ≤ 0.05) in the mean coagulation time between plasmas for a group of isolates are denoted 
by the superscript “*”.  Significant differences (p ≤ 0.05) in the mean coagulation time with dog plasma between 














significantly faster than rabbit plasma, whereas no significant differences were found among 
canine isolates (Table 3.1). 
 Previous studies have shown that S. aureus isolates coagulate plasmas of different origins 
to varying degrees, including false negatives, suggesting that multiple plasmas may need to be 
used (Live 1972; Adesiyun and Shehu 1985).  However, because these data were collected in the 
1970s and 1980s before some staphylococcal species (e.g, S. pseudintermedius) were recognized, 
the identity of those collections and the specificity of the data to S. aureus are uncertain.  
Additionally, because direct comparisons between dog and rabbit plasma have not been reported, 
this study fills an important gap in the literature.     
 The current study demonstrates that there are significant differences in the coagulase test 
using dog and rabbit plasmas. Although the time to clot dog plasma was significantly faster 
overall, suggesting an intrinsic superiority to rabbit plasma, there was also variability between 
isolates from different host species, giving credence to the biotype hypothesis.  Although no 
false-negatives are described in the present report, the archived samples tested were initially 
identified using rabbit plasma and may not be representative of all clinical isolates, therefore 
potentially overestimating the utility of rabbit plasma. 
 Significant differences were not found between canine and human isolates, possibly 
reflecting the previously described genetic similarity between canine and human S. aureus 
collected from a single geographic location (Weese and van Duijkeren 2010).  Additionally, the 
significant differences found in the time to clot dog plasma between bovine and human isolates 
is consistent with previously reported genetic dissimilarities between bovine and human strains 




techniques for evaluating the relatedness of S. aureus such as spa typing and multilocus 
sequence typing. 
 Investigators should be aware of the potential limitations of only using rabbit plasma, 
particularly when testing samples from different hosts.  Future studies including plasmas and 
prospectively collected isolates from a greater number of hosts should be done to define the 
utility of various plasmas for different diagnostic applications. 
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4.1 The study 
 Staphylococcus aureus is a promiscuous colonizer/pathogen, it lacks host specificity and 
colonizes various anatomical sites.  To better understand the complex epidemiology of S. aureus 
in dogs, sensitive screening protocols, including which body sites to sample, are required.  Extra-
nasal colonization of humans is well recognized; 27% of carriers are not nasally colonized 
including 12.8% - 20% and 10% - 17.1% who are exclusively pharyngeally and enterally 
colonized respectively (Eveillard, de Lassence et al. 2006; Mertz, Frei et al. 2007; Batra, 
Eziefula et al. 2008; Mody, Kauffman et al. 2008). The relative importance of colonization at 
these sites has not been evaluated in dogs (Weese and van Duijkeren 2010). In this study, the 
prevalence of pharyngeal, nasal and rectal S. aureus carriage among healthy dogs was 
determined.  One hundred sixty seven clinically healthy dogs presenting for vaccinations and 
annual physical examinations to the Western College of Veterinary Medicine, Veterinary 
Teaching Hospital were sampled. Using sterile swabs (BBL CultureSwab, Sparks, MD) the 
pharynx, nares and rectum were sampled. Sterile saline from single use 5 ml vials (Hospira 
Healthcare Corporation, Montreal, Canada) was used to moisten swabs prior to nasal sampling.  
 All samples were processed within five hours of collection. Each swab was plated on 
CHROMagar Staph aureus (CHROMagar, Paris, France) and mannitol salt agar (Becton, 
Dickenson and Company, Sparks, MD), both with and without 4µg/ml oxacillin (Sigma-Aldrich, 
St. Louis, MO), and Trypticase Soy Agar with 5% sheep’s blood (Becton, Dickenson and 
Company, Sparks, MD) and incubated at 35°C overnight. Each swab was then broken off into a 
tube containing 2 ml of enrichment broth with 75g/L NaCl which, after overnight incubation at 
35°C, was plated onto the same five media (Weese 2007). Growth on solid media was evaluated 




biochemical tests and analysis of the cpn60 and 16S rRNA gene sequences; previously published 
primers were used (Dorsch and Stackebrandt 1992; Hill, Paccagnella et al. 2006). All isolates 
were confirmed to be methicillin susceptible or resistant by both oxacillin broth micro-dilution 
susceptibility testing (Sensititre, Trek Diagnostic Systems, Cleveland, OH) according to CLSI 
guidelines, and by screening for the mecA gene using published primers (de Neeling, van 
Leeuwen et al. 1998; CLSI 2008). 
 Of the 167 dogs sampled, 17 (10.2%) were positive for S. aureus, one of which was 
methicillin resistant. Among these dogs, 10 were pharyngeally colonized while 13 and seven 
were nasal and rectal carriers respectively (Table 4.1). From the MRSA colonized dog, only a 
single colony was isolated from CHROMagar without oxacillin.  The MRSA was only detected 
after susceptibility testing; false negatives on selective media have previously been attributed to 
low bacterial numbers (Tande, Garo et al. 2008). The single phenotypically identified MRSA 
was mecA positive while all other isolates were negative.  
 Among S. aureus carriers, 5.9%, 17.6% and 17.6% were exclusively pharyngeally, 
rectally and nasally colonized respectively (Table 4.1). Using all three sites as the gold standard, 
the sensitivity of sampling the nares + rectum was 94.1%, nares + pharnx 82.4% and pharynx + 
rectum 82.4%. There is increasing interest in canine S. aureus colonization therefore sensitive 
screening protocols including multiple anatomic sites are necessary to accurately define the 




















1 + Neg + 
2 + Neg + 
3 + Neg + 
4 Neg + Neg 
5 Neg + + 
6 + Neg + 
7 Neg Neg + 
8 + + + 
9 + Neg + 
10 Neg + Neg 
11 + + + 
12* Neg Neg + 
13 + Neg + 
14 Neg + Neg 
15 + + + 
16 Neg Neg + 
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5.1 Summary  
 Staphylococcus aureus is one of the most common causes of infection in people and is 
increasingly recognized in dogs.  The increasing prevalence of methicillin resistant S. aureus 
(MRSA) is complicating the treatment of these infections.  Panton Valentine leukocidin (PVL), a 
toxin involved in the pathogenesis of necrotic syndromes in people may be partially responsible 
for the rise of MRSA.  Canine and human S. aureus isolates from the same geographic area are 
genetically similar, indicating a common population and probably transmission.  The 
implications of increasing antimicrobial resistance complicated by interspecies transmission 
necessitates including both dogs and humans in S. aureus resistance surveillance studies.  A 
collection of 126 S. aureus isolates from people (51 MRSA and 48 MSSA) and dogs (18 
colonizing isolates and 9 clinical MRSA) were included. The minimum inhibitory concentrations 
(MIC) of a panel of 33 antimicrobials used in human and veterinary medicine were determined 
for all isolates.  No resistance to vancomycin, linezolid, daptomycin, quinupristin/dalfopristin or 
nitrofurantoin was found.  A wide range of antibiograms were found including resistance to 
between 0-12 drugs (0-6 drug classes).  Outstanding antibiograms included a canine MRSA 
resistant to rifampin and a human MRSA resistant to chloramphenicol.  Inducible clindamycin 
resistance (iCR) was found among 78% and 4% of canine and human MRSA and 17% and 25% 
of canine colonizing and human methicillin susceptible S. aureus (MSSA) respectively.  
Resistance to mupirocin was only found among human isolates including 20% of MRSA and 4% 
of MSSA.  While no canine isolates were PVL positive, 39% of human MRSA and 2% of MSSA 
carried the gene.  The bidirectional transmission of S. aureus between people and dogs 





5.2 Introduction  
 Staphylococcus aureus commonly causes infections in people and is increasingly 
recognized in dogs (Weese and van Duijkeren 2010).  Readily adapting to antimicrobial selection 
pressure, penicillin resistance emerged shortly after its introduction, initially in hospitals 
followed by dissemination into the community (Woodford 2005).  Similarly, the development of 
MRSA in hospitals was followed by community dissemination, where it now predominates as a 
cause of skin and soft tissue infections in some areas (Stenstrom, Grafstein et al. 2009).  The 
ecology of S. aureus is complex and includes multiple host species. Genetic studies have shown 
that canine and human MRSA from the same region tend to be related, indicating a shared 
population (Weese and van Duijkeren 2010). Furthermore, indistinguishable isolates recovered 
from infections in people and dogs highlights the clinical importance of this shared population 
(Manian 2003; Faires, Tater et al. 2009).  Despite the increasing incidence in people, canine 
MRSA infections are still rarely identified in Western Canada. This report includes the first 
clinical canine isolates from our region (Simor, Gilbert et al. 2010).  Interspecies transmission of 
S. aureus highlights the importance of including human and canine isolates in future resistance 
surveillance. 
 Often associated with community associated MRSA (CA-MRSA), Panton Valentine 
leukocidin (PVL) plays a role in the pathogenesis of certain necrotic syndromes in people 
(Labandeira-Rey, Couzon et al. 2007).   While the activity of PVL is species specific, and its role 
in canine infection is unknown, its human health implications necessitate monitoring the 
dissemination of this toxin (Loffler, Hussain et al. 2010).  
 While antimicrobial resistance surveillance programmes in Canada exist for human 




analysis difficult (Canada 2008).  Foodborne pathogens are actively surveilled in Canada and the 
United States, while other veterinary resistance reservoirs including companion animal 
staphylococci are not addressed (Canada 2007; FDA 2007).  While canine staphylococci in 
Saskatoon have historically been remarkably susceptible, the recent isolation of methicillin 
resistant organisms indicates that this may be changing  (Ball, Rubin et al. 2008; Rubin, Ball et 
al. 2011; Rubin and Gaunt 2011).  The purpose of this study was to determine the susceptibility 
of canine and human S. aureus to a panel of 33 antimicrobials and to determine the frequency of 
PVL positive isolates in this collection. 
 
5.3 Materials and methods 
5.3.1 Bacterial collection 
 A collection of 126 canine and human S. aureus from Saskatoon, Canada were tested.  
The 27 canine samples included the nine MRSA isolates (CCMR) corresponding to all canine 
MRSA infections identified at our hospital in 2006 and 2008.  These MRSA, while cultured from 
different patients, included isolates from three outbreaks and are therefore not all independent 
samples.  Eighteen colonizing isolates (CCOL) were also tested including one MRSA. These 
were isolated as previously described from epidemiologically unrelated healthy dogs presenting 
to the teaching hospital for routine health checks in 2008 (Rubin and Chirino-Trejo 2010).  
Isolates from human infections were collected from the diagnostic lab at Royal University 
Hospital in Saskatoon, Canada.  Fifty one MRSA (HCMR) and 48 methicillin susceptible S. 
aureus (MSSA) (HCMS) were collected from serial, diagnostic samples from unique patients in 
late 2008 and early 2009.  Isolates were identified using standard biochemical tests, and were 




5.3.2 Antimicrobial susceptibility testing 
 Using the Sensititre system (Trek Diagnostics, Cleveland, OH), antimicrobial MICs of 31 
drugs were determined (Table 5.1).  Antimicrobial MICs were classified as susceptible or 
resistant according to CLSI guidelines (CLSI 2008; CLSI 2008).  Mupirocin (MUP) and fusidic 
acid (FUS) susceptibility was tested by disk diffusion according to BSAC guidelines (Andrews 
2008).  Mupirocin MICs were determined by E-test (AB biomérieux, Solna, Sweden) for all 
resistant isolates to differentiate between high and low level resistance.  Isolates resistant to 
erythromycin and susceptible to clindamycin (ERCS) were tested for inducible resistance (iCR) 
according to CLSI guidelines (CLSI 2008).  For quality control, S. aureus ATCC 29213 and 
ATCC 25923, Enterococcus faecalis ATCC 29212 and Escherichia coli ATCC 25922 were 
used.   
 
5.3.3 Screening for Panton Valentine Leukocidin and mecA 
 All isolates were screened by PCR for mecA using previously published primers S. 
aureus ATCC 43300 and S. aureus ATCC 29213 were used as positive and negative controls 
respectively (Table 5.2) (de Neeling, van Leeuwen et al. 1998).  All isolates were screened for 
PVL by PCR using previously published primers; S. aureus ATCC 49775 and S. aureus ATCC 
29213 was used as positive and negative controls respectively (Table 5.2) (Lina, Piemont et al. 








Table 5.1. Antimicrobial classes, drugs and abbreviations of compounds for which minimum 








































Table 5.2 Primer sequences used to amplify mecA and PVL 
Name Sequence Reference 
Primers used to amplify mecA (de Neeling, van Leeuwen et al. 1998) 
MecA1 5’ GTT GTA GTT GTC GGG TTT GG -3’   
MecAC3 5’ CTT CCA CAT ACC ATC TTC TTT A -3’  
Primers used to amplify PVL (Lina, Piemont et al. 1999) 
luk-PV-1 5’ ATC ATT AGG TAA AAT GTC TGG ACA TGA TCC A -3’  
























5.4 Results  
 While resistance to 10 antimicrobial classes including macrolide/lincosamide/ketolides, 
tetracyclines, β-lactams, aminoglycosides, phenicols, fluoroquinolones, rifamycins, 
sulfonamides, mupirocin and fusidic acid  was found, no isolates resistant to VAN, LZD, QDA, 
DAP or NIT were identified.  CCOL isolates were resistant to 0-8 drugs (0-3 classes) while 
HCMS were resistant to 0-9 drugs (0-5 classes) (Figure 5.1).  Multidrug resistance (resistance to 
three or more classes) was found in 6% of CCOL and 15% of HCMS. Among CCOL, 11% were 
pan-susceptible and a further 6% and 11% were only resistant to FUS and PEN respectively.  
Similarly, 17% of HCMS were pan-susceptible.   
 Resistance to PEN and AMP were commonly encountered among HCMS (77% and 73%) 
(Figure 5.2) and CCOL (78% and 67%) (Figure 5.3) respectively.  Half of CCOL and 44% of 
HCMS were only resistant to PEN and AMP.  Resistance to ERY and CLI was next most 
common among HCMS and CCOL, occurring in 31% and 17% of isolates, respectively.  The 
majority of these isolates, 80% and 100% respectively, were iCR.  Fluoroquinolone resistance 
was rare among both HCMS and CCOL, only a single isolate of each was MOX resistant.  No 
CCOL were resistant to GMS, TET or SXT (Figure 5.3), while a single HCMS was resistant to 
all three of these drugs (Figure  5.2).  Neither CFC nor RIF resistance was found among HCMS 









Figure 5.1 Antibiograms of canine colonizing Staphylococcus aureus (CCOL), canine clinical 




Drugs with British Society for Antimicrobial Chemotherapy (mupirocin and fusidic acid) or Clinical and Laboratory 
Standards Institute (all others) resistance breakpoints are included.  Resistance is indicated by blacked out cells in 
that drugs column.  Inducible clindamycin resistance (iCR) is included in a column separate from clindamycin.  The 
number of isolates in each isolate collection with a given antibiogram is indicated on the left in each isolate 
collections column. 





Antimicrobial minimum inhibitory concentration (MIC) distribution of human MSSA (n=48) 





β-Lactams Ampicillin    9 4 1 13 8 5 5 3    1 8 72.9 
Ceftiofur     1 38 9        1 2 0 
Oxacillin     31 15 1 1       ≤0.25 0.5 0 




Clindamycin     45       3   ≤0.25 ≤0.25 6.3 
Erythromycin*     15 18    15     0.5 8 31.2 
Telithromycin*     44 1   3      ≤0.25 ≤0.25 6.2 
Tilmicosin         45     3 ≤4 ≤4  
Tulathromycin         21 17 2 2  6 8 ≥128  
Tylosin       14 30  1   3  2 2  
Fluoroquinolones Ciprofloxacin*       45 1 2      ≤1 ≤1 4.1 
Danofloxacin    19 22 5  2       0.25 0.5 
Enrofloxacin*    29 15 3  1 1      ≤0.12 0.5 2 
Gemifloxacin 12 28 6   2         0.03 0.06  
Moxifloxacin     46  1   1     ≤0.25 ≤0.25 2 
Tetracyclines Chlortetracycline      45 1  1  1    ≤0.5 ≤0.5  
Oxytetracycline      42 4    2    ≤0.5 1  
Tetracycline        46   1 1   ≤2 ≤2 4.2 
Aminoglycosides Gentamicin       47     1   ≤1 ≤1 2 
Neomycin         43 1 1 1 2  ≤4 8  
Spectinomycin             13 35 ≥128 ≥128  
Phenicols Chloramphenicol*          43 5    8 16 0 
Florfenicol        1 46 1     4 4  
Peptide  Daptomycin      48         ≤0.5 ≤0.5 0 
Oxazolidonone Linezolid       3 44 1      2 2 0 
Nitroimidazole Nitrofurantoin*            48   ≤32 ≤32  
Streptogramin QDA†      47 1        ≤0.5 ≤0.5 0 
Rifamycin Rifampin      48         0.5 0.5 0 
Sulfonamide SXT§      46   2      ≤0.5 ≤0.5 4.1 
Pleuromutilin Tiamulin      10 36 2       1 1  
Glycopeptide Vancomycin       45 3       ≤1 ≤1 0 
Cells corresponding to drug concentrations (µg/ml) tested are un-shaded.  Isolates inhibited at the lowest drug concentration should be considered to have an 
MIC of less than or equal to that concentration.  Isolates not inhibited at the highest concentration tested should be considered to have an MIC of greater than or 
equal to the first concentration beyond the tested range.  For example, isolates uninhibited by 8µg/ml of ampicillin are presumed to have an MIC of ≥168µg/ml.  
Cells with double borders correspond to Clinical and Laboratory Standards Institute resistance breakpoints for all drugs except daptomycin and linezolid where 











Antimicrobial minimum inhibitory concentration (MIC) distribution of canine colonizing Staphylococcus aureus (n=18) 





β-Lactams Ampicillin    4 2  3 2 6  1    1 4 67 
Ceftiofur      1 14 2   1    1 2 6 
Oxacillin     11 6     1    ≤0.25 0.5 6 




Clindamycin     17  1        ≤0.25 ≤0.25 0 
Erythromycin*     7 8    3     0.5 8 17 
Telithromycin*     17   1       ≤0.25 ≤0.25 0 
Tilmicosin         17   1   ≤4 ≤4  
Tulathromycin         12 5    1 4 8  
Tylosin       8 9     1  1 2  
Fluoroquinolones Ciprofloxacin*       17  1      ≤1 ≤1 6 
Danofloxacin    11 5 1  1       ≤0.12 0.5  
Enrofloxacin*    13 2 1 1  1      ≤0.12 1 6 
Gemifloxacin 5 9 3   1         0.03 0.06  
Moxifloxacin     17     1     ≤0.25 ≤0.25 6 
Tetracyclines Chlortetracycline      18         ≤0.5 ≤0.5  
Oxytetracycline      17 1        ≤0.5 ≤0.5  
Tetracycline        18       ≤2 ≤2 0 
Aminoglycosides Gentamicin       17 1       ≤1 ≤1 0 
Neomycin         17   1   ≤4 ≤4  
Spectinomycin             9 9 64 ≥128  
Phenicols Chloramphenicol*          17 1    ≤8 ≤8 0 
Florfenicol        1 17      ≤4 ≤4  
Peptide  Daptomycin      18         ≤0.5 ≤0.5 0 
Oxazolidonone Linezolid        15 3      2 4 0 
Nitroimidazole Nitrofurantoin*            18   ≤32 ≤32 0 
Streptogramin QDA†      16 2        ≤0.5 1 0 
Rifamycin Rifampin      18         0.5 0.5 0 
Sulfonamide SXT§      18         ≤0.5 ≤0.5 0 
Pleuromutilin Tiamulin      8 8   2     0.25 8  
Glycopeptide Vancomycin       18        ≤1 ≤1 0 
Cells corresponding to drug concentrations (µg/ml) tested are un-shaded.  Isolates inhibited at the lowest drug concentration should be considered to have an 
MIC of less than or equal to that concentration.  Isolates not inhibited at the highest concentration tested should be considered to have an MIC of greater than or 
equal to the first concentration beyond the tested range.  For example, isolates uninhibited by 8µg/ml of ampicillin are presumed to have an MIC of ≥168µg/ml.  
Cells with double borders correspond to Clinical and Laboratory Standards Institute resistance breakpoints for all drugs except daptomycin and linezolid where 








 The CCMR were resistant to 6-9 drugs (3-6 classes) and HCMR were resistant to 3-12 
drugs (1-6 classes); 100% and 45% were multidrug resistant, respectively (Figure 5.1).  All 
MRSA (mecA positive) were phenotypically resistant to PEN, AMP and OXA while all OXA 
susceptible isolates were mecA negative.  Resistance to CLI including iCR was very common 
(89% of CCMR and 35% of HCMR isolates) (Figure 5.1).  Resistance to fluoroquinolones was 
also common; 56% of CCMR (Figure 5.5) and 26% of HCMR were MOX resistant (Figure 5.4).  
Resistance to CFC and RIF were found in single HCMR (Figure 5.4) and CCMR (Figure 5.5) 
isolates, respectively.  While TET and SXT resistance was found only in a single CCMR, these 
phenotypes were common among HCMR, occurring in 16% and 14% of isolates respectively.  
Resistance to GMS was found in 14% of HCMR and 11% of CCMR. 
 For drugs without CLSI resistance breakpoints, categorical analyses were not done.  
Isolates resistant to ERY, CLI and TEL had elevated TYL, TUL and TIL MICs compared to 
ERY, CLI and TEL susceptible isolates.  Likewise, OXY and CLO MIC distributions were 
similar to TET but those isolates resistant to TET were not inhibited by the highest 
concentrations of OXY and CLO tested.  MICs of NEO varied widely, and inconsistently 
compared to GMS.  Isolates susceptible and resistant to GMS inhibited at the lowest 
concentration of NEO, or entirely uninhibited by NEO were identified.  With the exception of 
two CCOL and one HCMR, all isolates were inhibited by the lowest three concentrations of TIA 
tested.   
 Resistance to MUP was only found among human isolates including 4% of HCMS and 
20% of HCMR and all isolates had MICs ≥1024 µg/ml indicating high level resistance (Andrews 
2008).  Resistance to FUS was found in all collections including 17% of HCMS, 20% of HCMR, 




Antimicrobial minimum inhibitory concentration (MIC) distribution of human MRSA (n=51) 





β-Lactams Ampicillin        1 1 4 45    ≥16 ≥16 100 
Ceftiofur        2 13 20 16    8 ≥16 70.6 
Oxacillin          2 49    ≥16 ≥16 100 




Clindamycin     34 1      16   ≤0.25 ≥32 31.4 
Erythromycin*     2 22    27     8 8 52.9 
Telithromycin*     35   1 15      ≤0.25 ≥4 29.4 
Tilmicosin         35    1 15 ≤4 ≥128  
Tulathromycin         6 27    18 8 ≥128  
Tylosin       6 29     15  2 ≥64  
Fluoroquinolones Ciprofloxacin*       28  23      ≤1 ≥4 45.1 
Danofloxacin    7 21   23       0.25 ≥2 
Enrofloxacin*    10 18    23      0.25 ≥4 45.1 
Gemifloxacin 3 25    23         0.03 ≥0.5  
Moxifloxacin     28   10  13     ≤0.25 ≥8 25.5 
Tetracyclines Chlortetracycline      39  4   8    ≤0.5 ≥16  
Oxytetracycline      34 5  4  8    ≤0.5 ≥16  
Tetracycline        39 4   8   ≤2 ≥32 15.7 
Aminoglycosides Gentamicin       44    1 6   ≤2 ≥32 13.7 
Neomycin         29  1  21  ≤4 ≥64  
Spectinomycin             27 24 64 ≥128  
Phenicols Chloramphenicol*        1  30 19 1   8 16 2 
Florfenicol         39 12     4 8  
Peptide  Daptomycin      51         ≤0.5 ≤0.5 0 
Oxazolidonone Linezolid        47 4      2 2 0 
Nitroimidazole Nitrofurantoin*            51   ≤32 ≤32 0 
Streptogramin QDA†      43 8        ≤0.5 1 0 
Rifamycin Rifampin      51         ≤0.5 ≤0.5 0 
Sulfonamide SXT§      44    7     ≤0.5 ≥8 13.7 
Pleuromutilin Tiamulin      16 34   1     1 1  
Glycopeptide Vancomycin       50 1       ≤1 ≤1 0 
Cells corresponding to drug concentrations (µg/ml) tested are un-shaded.  Isolates inhibited at the lowest drug concentration should be considered to have an 
MIC of less than or equal to that concentration.  Isolates not inhibited at the highest concentration tested should be considered to have an MIC of greater than or 
equal to the first concentration beyond the tested range.  For example, isolates uninhibited by 8µg/ml of ampicillin are presumed to have an MIC of ≥168µg/ml.  
Cells with double borders correspond to Clinical and Laboratory Standards Institute resistance breakpoints for all drugs except daptomycin and linezolid where 











Antimicrobial minimum inhibitory concentration (MIC) distribution of clinical canine MRSA (n=9) 





β-Lactams Ampicillin           9    16 16 100 
Ceftiofur           9    16 16 100 
Oxacillin           9    16 16 100 




Clindamycin     8       1   0.25 32 11.1 
Erythromycin*      1    8     8 8 88.9 
Telithromycin*     8    1      0.25 4 11.1 
Tilmicosin         8     1 4 128  
Tulathromycin         2 5    2 8 128  
Tylosin       4 4     1  2 64  
Fluoroquinolones Ciprofloxacin*       3  6      4 4 66.7 
Danofloxacin    1 2   6       2 2  
Enrofloxacin*    1 2    6      4 4 66.7 
Gemifloxacin  2 1   6         0.5 0.5  
Moxifloxacin     3   1  5     8 8 55.6 
Tetracyclines Chlortetracycline      8     1    0.5 16  
Oxytetracycline      4 4    1    1 16  
Tetracycline        7 1   1   2 32 11.1 
Aminoglycosides Gentamicin       7 1    1   1 32 11.1 
Neomycin         4   4 1  32 64  
Spectinomycin             2 7 128 128  
Phenicols Chloramphenicol*          3 6    16 16 0 
Florfenicol         6 3     4 8  
Peptide  Daptomycin      9         0.5 0.5 0 
Oxazolidonone Linezolid        3 6      4 4 0 
Nitroimidazole Nitrofurantoin*            9   32 32 0 
Streptogramin QDA†      7 2        0.5 1 0 
Rifamycin Rifampin      8   1      0.5 4 11.1 
Sulfonamide SXT§      8    1     0.5 8 11.1 
Pleuromutilin Tiamulin      3 6        1 1  
Glycopeptide Vancomycin       9        1 1 0 
Cells corresponding to drug concentrations (µg/ml) tested are un-shaded.  Isolates inhibited at the lowest drug concentration should be considered to have an 
MIC of less than or equal to that concentration.  Isolates not inhibited at the highest concentration tested should be considered to have an MIC of greater than or 
equal to the first concentration beyond the tested range.  For example, isolates uninhibited by 8µg/ml of ampicillin are presumed to have an MIC of ≥168µg/ml.  
Cells with double borders correspond to Clinical and Laboratory Standards Institute resistance breakpoints for all drugs except daptomycin and linezolid where 












 The increasing incidence of MRSA in people is resulting in increased costs, length of 
hospitalization and mortality (Abramson and Sexton 1999; Laupland, Ross et al. 2008; Simor, 
Gilbert et al. 2010).  Perhaps because canine MRSA infections are most frequently associated 
with non-life threatening conditions, the increased mortality associated with MRSA infections in 
human beings were not found in dogs (Faires, Traverse et al. 2010).  Interspecies MRSA 
transmission necessitates integrated surveillance programs to actively monitor the emergence and 
dissemination of resistance among human and veterinary staphylococci.  The close contact 
between people and dogs is underappreciated as a means of transmission for potential pathogens 
and requires further study. 
 By definition, MRSA are resistant to all β-lactam antimicrobials, including the 
penicillins, cephalosporins and carbapenems (Woodford 2005).  Orally bioavailable drugs 
including doxycycline, clindamycin and chloramphenicol are used to treat resistant 
staphylococcal infections in dogs, though the efficacy of these agents is also threatened.  Failure 
to express clindamycin resistance in vitro presents unique challenges in iCR; without exposure to 
erythromycin the misclassification of an isolate as clindamycin susceptible is possible.  In vivo 
induction of resistance and subsequent treatment failure has been described, highlighting the 
importance of iCR (Siberry, Tekle et al. 2003).  Practitioners should suspect iCR in isolates that, 
without specialized susceptibility tests, appear to be erythromycin resistant and clindamycin 




susceptibility to both clindamycin and erythromycin are not always reported, it may be prudent 
to suspect iCR in isolates resistant to erythromycin (Faires, Gard et al. 2009).  The high 
proportion of canine MRSA (78%) which were iCR may reflect a bias collection, these isolates 
are not independent and were collected from three.  In contrast, 17% of canine colonizing 
isolates were iCR, consistent with previous reports (Faires, Gard et al. 2009).  The proportion of 
human MSSA that were iCR (22.9%) was greater than MRSA (3.9%), similar to previously 
reported studies (Levin, Suh et al. 2005; Yilmaz, Aydin et al. 2007).  The prevalence of iCR 
described in the present study, particularly among canine isolates and human MSSA, highlights 
the potential impact of this phenotype in our region.   
 Since the recognition of MRSA in the 1960’s, vancomycin has been the mainstay of anti-
MRSA therapy (Song 2008).  Recently, MRSA isolates with intermediate susceptibility to 
vancomycin have emerged, and although rare, vancomycin resistant MRSA have also been 
reported (Finks, Wells et al. 2009).  Canine S. aureus isolates with intermediate susceptibility or 
resistance to vancomycin have not yet been reported.  No isolates resistant to vancomycin, 
linezolid, quinupristin/dalfopristin or daptomycin were found in this study.   
 Fluoroquinolone resistance was common among both HCMR and CCMR.  As 
fluoroquinolone usage has been identified as a risk factor for MRSA acquisition in people and 
dogs, it may be prudent to avoid these drugs when other therapeutic options are available 
(Weber, Gold et al. 2003; Dancer 2008; Faires, Traverse et al. 2010).  No isolates simultaneously 
resistant to tetracycline, chloramphenicol and trimethoprim/sulfamethoxazole, drugs commonly 
used to treat canine MRSA infections, were found.  Gentamicin resistance was uncommon 




resistant.  The gentamicin resistant canine isolate was also the only rifampin resistant isolate 
from any source. 
 Topical antimicrobials are commonly used for treating superficial MRSA infections and 
nasal decolonization (Enoch, Karas et al. 2009; McConeghy, Mikolich et al. 2009).  Previously, 
50% of MRSA from Northern Saskatchewan were reported to be mupirocin resistant, higher than 
elsewhere in Canada (Mulvey, MacDougall et al. 2005; Simor, Stuart et al. 2007).  Whether the 
relatively low prevalence of mupirocin resistance found in this study is due to recent changes in 
mupirocin usage or geographic variability is unknown.  No canine isolates were resistant to 
mupirocin perhaps because mupirocin is infrequently used in dogs due to its oily preparation 
reducing the selection pressure for resistance.  Fusidic acid resistance was found in both canine 
and human isolates.  
 The incidence of CA-MRSA infections has rapidly increased in Canada over the last 
decade (Simor, Gilbert et al. 2010).  Shown to play a role in necrotizing syndromes in people, 
PVL is associated with CA-MRSA and is also increasingly prevalent (Labandeira-Rey, Couzon 
et al. 2007).  Whether reflecting its true prevalence or the small number of samples is unknown 
but PVL was not found in any canine isolates.  The activity of PVL against canine neutrophils is 
unknown.  
 The ecology of S. aureus is complex, including bidirectional transmission between 
people and dogs.  The public health risks of canine MRSA and the canine health risks of human 
MRSA, combined with antimicrobial selection pressure in both species requires further study.  
The risks associated with using ‘top-shelf’ drugs like vancomycin for treating canine infections 
are ill defined, suggesting the need for a thorough risk assessment (Weese 2008).  Fortunately, 




topical medications such as Burrow’s solution which, by altering the ear environment is effective 
against a broad spectrum of pathogens irrespective of antimicrobial resistance (Kashiwamura, 
Chida et al. 2004; Faires, Traverse et al. 2010). 
 Susceptibility data for this extensive panel of drugs tested will be invaluable for future 
studies; few reports detailing S. aureus susceptibility to many of these drugs are available.  
Drugs in their infancy of clinical use, pleuromutilins, or without adequately defined resistance 
breakpoints such as neomycin were included. By presenting MIC distributions in addition to 
categorical (susceptible versus resistant) data, this study provides maximally comparable 
information.   
 While resistance surveillance is routine in Canada, its scope is limited and may not reflect 
what is seen in the community or by veterinarians.  Collaboration between veterinarians and 
human health professionals is essential for surveillance of this potential pathogen which has little 
regard for species barriers. 
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 In dogs, Staphylococcus pseudintermedius is a common colonizer and is associated with 
pyoderma, otitis externa and urinary tract infections.  In the current study, nasal, pharyngeal and 
rectal swabs were taken from 175 healthy dogs and cultured for S. pseudintermedius.  The 
organism was found in 153 (87.4%) dogs including individuals exclusively colonized in the 
nares (n=1), pharynx (n=16) and rectum (n=17).  Antimicrobial susceptibility testing revealed 
that a remarkably susceptible population: 46.4% of isolates, were susceptible to all drugs tested, 
and resistance to penicillin (39.9%) and tetracycline (23.5%) were most common.  No methicillin 
(oxacillin)-resistant isolates were identified.  Although 3.3% of isolates were erythromycin 
resistant, no inducible clindamycin resistance was found.  The data provide a baseline for future 
resistance surveillance and indicate that multiple body sites including at least the pharynx and 
rectum, should be included. 
 
6.2 The study 
 Staphylococcus pseudintermedius, first described as distinct from Staphylococcus 
intermedius in 2005, is a coagulase-positive staphylococcal species frequently associated with 
pyoderma, otitis externa, urinary tract infections (UTI), and opportunistically infected sites in 
dogs (Werckenthin, Cardoso et al. 2001; Ball, Rubin et al. 2008; Devriese, Hermans et al. 2009; 
Weese and van Duijkeren 2010).  Colonization with S. pseudintermedius is common, and is 
reported in up to 68% of healthy dogs (Griffeth, Morris et al. 2008).  Although the nares, mouth, 
rectum, groin, and forehead have been sampled in previous studies, the prevalence of single site 
colonization has not been evaluated (Hanselman, Kruth et al. 2007; Griffeth, Morris et al. 2008).  




tract, play a role in Staphylococcus aureus colonization, although some individuals are single site 
colonized (Eveillard, de Lassence et al. 2006; Mertz, Frei et al. 2007; Batra, Eziefula et al. 2008; 
Mody, Kauffman et al. 2008; Rubin and Chirino-Trejo 2010).  Knowledge of sites of 
colonization is essential for conducting surveillance studies; failing to sample relevant sites may 
result in false negatives and an underestimation of itsprevalence.  Conversely, the increased 
expense and time required for excessive sampling is undesirable. 
 Antimicrobial resistance, including methicillin resistance (MRSP), is increasing among S. 
pseudintermedius (Weese and van Duijkeren 2010).  Although clinical S. pseudintermedius 
isolates from the Saskatoon region have remained largely susceptible, the recent identification of 
a multidrug-resistant MRSP from a canine UTI suggests that the locally prevalent resistance 
patterns are changing (Ball, Rubin et al. 2008; Rubin, Ball et al. 2011; Rubin and Gaunt 2011). 
 The purpose of the current study was to determine the relative prevalence of nasal, 
pharyngeal and rectal colonization of healthy dogs with S. pseudintermedius, and to characterize 
the antimicrobial susceptibility profiles of these isolates to an extensive panel of drugs.  
 Between May and November 2008, 175 dogs presenting to the Western College of 
Veterinary Medicine (Saskatoon, Saskatchewan, Canada) for routine health checks and 
vaccination were sampled.  One dog per household was included in the study.  Using individual, 
commercially prepared culturettes,a nasal, pharyngeal and rectal samples were taken.  Of the 175 
dogs sampled, it was not possible to collect all three specimens from eight fractious animals; 
therefore, only 167 dogs were completely sampled. 
 All samples were processed within 5 hr of collection.  Swabs were streaked on 
chromogenic S. aureus mediumb and mannitol salt agarc both with and without 4 μg/ml 




containing 2 ml of enrichment broth with 75 g/l sodium chloride (Weese 2007).  After overnight 
incubation at 35°C, broth cultures were inoculated onto the same five solid media to detect low 
bacterial numbers.  Plates were evaluated for growth at 24, 48 and 96 hr.  Identification of S. 
pseudintermedius was based on colony morphology on blood agar; Gram’s staining 
characteristics; the production of catalase, DNase and coagulase; and lack of hyaluronidase or 
acetoin production (Winn, Allen et al. 2006; Devriese, Hermans et al. 2009). 
 The susceptibility of 153 S. pseudintermedius isolates (one per dog) to 33 antimicrobials 
was tested using a commercially available system.e  The minimum inhibitory concentrations 
(MICs) of the following antimicrobials were determined: β-lactams: ampicillin (AMP), ceftiofur 
(CEF), penicillin (PEN), and oxacillin (OXA); macrolide/lincosamide/ketolides: clindamycin 
(CLI), erythromycin (ERY), telithromycin (TEL), tilmicosin (TIL), tulathromycin (TUL), and  
tylosin (TYL); fluotoquinolones: ciprofloxacin (CIP), danofloxacin (DAN), enrofloxacin (ENR), 
gemifloxacin (GEM), and moxifloxacin (MOX); tetracyclines: chlortetracycline (CLO), 
oxytetracycline (OXY), and tetracycline (TET); aminoglycosides:  gentamicin (GMS), neomycin 
(NEO), and spectinomycin (SPT); and other drug classes: chloramphenicol (CHL), daptomycin 
(DAP), florfenicol (FFC), linezolid (LZD), nitrofurantoin (NIT), quinupristin/dalfopristin 
(QDA), rifampin (RIF), trimethoprim/sulfamethoxazole (SXT), tiamulin (TIA), and vancomycin 
(VAN).  Clinical and Laboratory Standards Institute (CLSI) testing protocols and interpretive 
criteria were used for all drugs except oxacillin for which the newly implemented resistance 
breakpoint (0.5 µg/ml) was used (CLSI 2008; CLSI 2008; Papich 2010).  For drugs without 
CLSI resistance breakpoints, MICs were not categorically analyzed.  Mupirocin (MUP) and 
fusidic acid (FUS) susceptibilities were determined using the disk diffusion methodf according to 




for inducible clindamycin resistance (iCR) according to CLSI guidelines (CLSI 2008).  For 
quality control S. aureus American Type Culture Collection (ATCC) 29213, S. aureus ATCC 
25923, Enterococcus faecalis ATCC 29212 and Escherichia coli ATCC 25922 were used.  
 Staphylococcus pseudintermedius was identified from 153 of 175 dogs (87.4%) overall 
and in 148 of 167 (88.6%) of completely sampled dogs, higher than previously reported 
(Griffeth, Morris et al. 2008).  Nasal, pharyngeal and rectal colonization were identified in 75, 
124 and 121 dogs respectively (Figure 6.1).  A total of 1 (0.7%), 16 (10.5%), and 17 (11.1%) 
dogs were exclusively nasally, pharyngeally and rectally colonized respectively.  Using all three 
sites as the gold standard, the sensitivity of sampling the nares + rectum was 89.2%, nares + 
pharynx 88.5% and the pharynx and rectum 99.3%.  To maximize the sensitivity of S. 


































 Susceptibility to all drugs was the most common phenotype identified, including 71 
isolates (46.4%) (Table 6.1).  No resistance to OXA (MRSP), CEF, GMS, MOX, CIP, ENR, 
CHL, SXT, RIF, NIT, VAN, LZD, QDA, DAP or FUS was found (Figure 6.2).  No MRSP were 
identified, although these isolates were not screened for mecA, the gene conferring methicillin 
resistance. However, susceptibility to oxacillin is reported to be 97% sensitive in detecting 
methicillin resistance and was considered sufficient for the purposes of this study (Schissler, 
Hillier et al. 2009).  Resistance to PEN and TET was found most commonly, occurring in 39.9% 
and 23.5% of isolates respectively.  However, nearly half of PEN-resistant (30 of 61) and half of 
TET-resistant (18 of 36) isolates were resistant to only that one drug.  Five isolates (3.6%) were 
macrolide resistant including a single isolate only resistant to ERY.  Two of four CLI-resistant 
isolates were also PEN resistant but remained susceptible to TET.  No iCR was found.  A single 
isolate resistant to MUP was identified, which was also resistant to PEN, AMP, and TET, 
making it the only multidrug-resistant isolate (resistant to three or more antimicrobial classes).  
High rates of MUP resistance (>50%) have been reported among human MRSA in 
Saskatchewan, but little is known about the susceptibility of canine staphylococci to this drug 
(Mulvey, MacDougall et al. 2005).  No isolates were simultaneously resistant to β-lactams, 
tetracyclines, and macrolides.  A previous study that included clinical canine S. 
pseudintermedius isolates from Saskatoon had reported lower levels of PEN resistance, but a 
higher prevalence of TET, ERY, CLI and SXT resistance (Rubin, Ball et al. 2011).  The lack of 
resistance to the fluoroquinolones, GMS, CHL and RIF is consistent with earlier studies from 






Table 6.1. Relative frequency of susceptibility profiles 
 
Resistance Phenotype Number (%) of isolates 
Susceptible to all drugs test 71 (46.4%) 
PEN 30 (19.6%) 
TET 18 (11.8%) 
PEN + TET 14 (9.2%) 
PEN + AMP 11 (7.2%) 
PEN + AMP + TET 3 (2.0%) 
PEN + ERY + CLI + TEL 2 (1.3%) 
ERY + CLI + TEL 2 (1.3%) 
ERY  1 (0.7%) 




























Figure 6.2 Antimicrobial minimum inhibitory concentration (MIC) distribution of 
Staphylococcus pseudintermedius (n=153) 
 
 
Cells corresponding to concentrations tested are outlined in bold. The number of isolates inhibited at each 
concentration are noted in each cell; isolates inhibited at the lowest concentration tested should be considered to 
have an MIC less than or equal to that concentration. Cells corresponding to Clinical and Laboratory Standards 
Institute resistance breakpoints are shaded; for daptomycin (DAP) and linezolid (LZD), susceptible breakpoints are 
shaded. Erythromycin (ERY), clindamycin (CLI), tylosin (TYL), tulathromycin (TUL), tilmicosin (TIL), 
telithromycin (TEL), quinupristin/dalfopristin (QDA), ampicillin (AMP), penicillin (PEN), oxacillin (OXA), 
ceftiofur (CEF), tetracycline (TET), oxytetracycline (OXY), chlortetracycline (CLO), gentamicin (GMS), neomycin 
(NEO), spectinomycin (SPT), moxifloxacin (MOX), gemifloxacin (GEM), ciprofloxacin (CIP), enrofloxacin (ENR), 
danofloxacin (DAN), vancomycin (VAN), DAP, LZD, chloramphenicol (CHL), florfenicol (FFC), 




 Because the current study is intended to serve as a baseline for S. pseudintermedius 
resistance surveillance, MICs of an extensive panel of drugs were determined for an extensive 
panel of drugs.  Monitoring of MICs allows changes in susceptibility below the resistance 
breakpoint to be detected compared with categorical analyses, which is relatively insensitive.  
Nearly uniform susceptibility to RIF, TIA, NIT, LZD, DAP, VAN, CIP, GEM, MOX, GMS, 
CEF, OXA and QDA was found, with all isolates inhibited by the lowest two concentrations 
tested, and below the resistance breakpoint, where available.  As old drug classes such as the 
pleuromutilins (retapamulinis now used for treating MRSA in humans) are “re-discovered”, 
historical susceptibility data for related compounds (tiamulin) will be invaluable in detecting the 
emergence of resistance (Yang and Keam 2008).  
 The inclusion of S. pseudintermedius isolated from healthy dogs may be more indicative 
of isolates involved in first-time community-associated infections than diagnostic samples, 
addressing an important gap in the literature.  The recognition of highly susceptible S. 
pseudintermedius is important in balancing the publication bias towards resistant organisms.  
The emphasis on resistance may encourage the empiric use of broad spectrum antimicrobials by 
both veterinarians and human health professionals.  Although empiric therapy is often 
unavoidable in clinical practice, it should be stressed that culture and susceptibility testing are 
cornerstones of prudent use. 
 Continued surveillance of antimicrobial resistance among coagulase positive 
staphylococci, including S. pseudintermedius, is required to monitor the emergence and 
dissemination of resistance.  Relatively little is known about the epidemiology, frequency of 




dogs.  Necessitated by both animal and public health concerns, more research is needed to 
address these important issues.  
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 Staphylococcus aureus is an important cause of morbidity and mortality in people, and is 
one of the most common causes of infection (Moet, Jones et al. 2007).    Colonization of healthy 
people with S. aureus is common with approximately 30% of individuals colonized nasally at a 
given time.  In contrast relatively few dogs (10%) are colonized (Kuehnert, Kruszon-Moran et al. 
2006; Rubin and Chirino-Trejo 2010).   
 Antimicrobial resistance has been complicating the treatment of S. aureus infections 
since the recognition of penicillin resistance in the 1940s (Woodford 2005).  The incidence of 
methicillin resistant Staphylococcus aureus (MRSA) infections in people has rapidly increased, 
and in some areas it now predominates in the community over methicillin susceptible S. aureus 
(MSSA) (Stenstrom, Grafstein et al. 2009; Simor, Gilbert et al. 2010; Weese and van Duijkeren 
2010).  In the last decade, the emergence of canine MRSA has received increasing attention and 
resistance in canine staphylococci and the implications of these organisms is now an intensively 
studied area (Leonard and Markey 2008; Weese and van Duijkeren 2010). 
 The genetic similarity of human and canine S. aureus, both MRSA and MSSA, suggests 
that there is a common bacterial population (Weese and van Duijkeren 2010).  Cases of MRSA 
transmission between people and dogs have been published, documenting the interspecies 
mobility of this organism (Simoons-Smit, Savelkoul et al. 2000; Manian 2003; van Duijkeren, 
Wolfhagen et al. 2005).  Transmission to immunocompromised people with increased 
susceptibility to infection is particularly concerning and institutionalized patients in contact with 
dogs as part of animal assisted therapy program may be at elevated risk (Lefebvre, Reid-Smith et 
al. 2009).  While the human health implications of zoonotic MRSA transmission are concerning, 




 Despite extensive investigations into the molecular epidemiology of human MRSA, 
relatively few studies comparing human and canine S. aureus have been published (Chambers 
and Deleo 2009; Grundmann, Aanensen et al. 2010; Weese and van Duijkeren 2010).  The 
purpose of this study was to compare canine and human S. aureus isolates using DNA 
fingerprinting techniques to address the hypothesis that dogs and people share a population of S. 
aureus.  Additionally, we aimed to define the common spa types found in dogs in both the 
Netherlands and Saskatoon, Canada, and those prevalent in humans in Saskatoon, Canada. 
 A collection of 144 S. aureus isolates from people and dogs in Saskatoon, Canada 
collected in 2008 and 2009 (n = 124) as well as canine isolates collected in Utrecht, the 
Netherlands between 2000 and 2008 (n = 20) were examined. Four different techniques were 
employed: amplified fragment length polymorphism (AFLP), 16S-23S inter-genic spacer typing 
(IS-typing), sequencing the hyper variable x-region of the Staphylococcal protein A gene (spa 
typing) and multilocus sequence typing (MLST).   
 Closely related and indistinguishable canine and human isolates were found, suggesting a 
common S. aureus population and interspecies transmission.  Two MRSA ST398, one human 
and one Dutch canine, and two human MSSA ST398 were identified.  Very little is known about 
the locally prevalent S. aureus lineages in Saskatoon, Canada and more research is required so 
that changes in S. aureus epidemiology can be better understood.  Furthermore, the complex 
epidemiology of S. aureus necessitates collaboration between veterinarians and human health 







7.2 Materials and methods 
 Twenty five canine isolates from the Western College of Veterinary Medicine (WCVM) 
in Saskatoon, Canada were included.  Nine clinical MRSA isolates from three nosocomial 
outbreaks at the WCVM in 2006 and 2008 and 15 MSSA and a single MRSA cultured in 2008 
from clinically healthy, epidemiologically unrelated, colonized dogs (nasal, pharyngeal or rectal 
colonization) were tested. Fifty one MRSA and 48 MSSA were collected from the diagnostic 
laboratory at Royal University Hospital in Saskatoon, Canada in 2008.  Isolates were collected 
from serial lab submissions from unique patients and were not selected based on site of infection.  
Finally, nine MRSA and 11 MSSA isolated from canine infections at a variety of body sites at 
the Faculty of Veterinary Medicine at Utrecht University from 2000 through 2009 were included. 
 DNA was isolated from overnight cultures on 5% Sheep’s Blood TSB agar (Oxoid, 
Cambridge, United Kingdom).  Bacterial suspensions were made to a density of McFarland 1 in 
Tris EDTA Buffer pH 8.0 and lysed with 25 µl lysostaphin (20 µg/ml) at 37°C for 30 minutes.  
Extraction and purification of DNA was done using the DNeasy kit (Qiagen, Germany).  This 
DNA preparation was used as template for AFLP.  For IS-typing, the DNA was diluted 1/10,000 
prior to PCR to optimize the amplicon signal. 
 An AFLP technique using specifically designed primers and adaptors was developed 
from previously published protocol (Savelkoul, Aarts et al. 1999). First, a simultaneous 
restriction-ligation step including equal parts (5 µl) purified genomic DNA and restriction-
ligation reaction mixture (Table 7.1) was carried out for 3 hours at 37°C.  Subsequently, ligated 
restriction fragments were diluted 1/20 and amplified by PCR using a FAM labeled Eco-C 




by capillary gel electrophoresis on an ABI Prism 3130xl Genetic Analyzer (Applied Biosystems, 
Foster City, CA).     
 PCR amplification of the variable length 16S-23S inter-genic spacer was done using 
published primers and cycle conditions (Table 7.3) (Budding, Vandenbroucke-Grauls et al. 
2010).  Labeled PCR products were resolved by capillary gel electrophoresis on an ABI Prism 
3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA). 
 Previously published primers and thermocycler conditions were used for spa typing and 
MLST (Table 7.3) (Enright, Day et al. 2000; Harmsen, Claus et al. 2003; Hallin, Friedrich et al. 
2009).  Reactions were carried out on single well isolated colonies grown overnight on trypticase 
soy agar + 5% sheep blood (Becton, Dickinson and Company, Sparks, MD).  PCR products were 
purified using the EZ-10 Spin Column PCR Purification Kit (Bio Basic Inc., Markham, Canada) 
according to the manufacturer’s instructions, and sent to a commercial facility for sequencing 




















Table 7.1 Reagents used in the restriction-ligation step of AFLP 
 
Reagent Concentration Volume per Sample 
T4 ligase buffer 10X 1.0 µl 
NaCl 0.5 M 1.0 µl 
Bovine serum albumin  1 mg/ml 0.5 µl 
Eco-AD adaptor 5 pmol/µl 0.2 µl 
Hha-AD adaptor 50 pmol/µl 0.2 µl 
T4 ligase 400 U/µl 0.2 µl 
EcoR1 restriction enzyme 20 U/µl 0.05 µl 
Hha1 restriction enzyme 20 U/µl 0.05 µl 
Ultra-pure water Pure 1.5 µl 


























Table 7.2 PCR master-mix used in the amplification step of AFLP 
 
Reagent Concentration Volume per Sample 
SuperTaq Buffer 10X 1.0 µl 
dNTP 10 mM 0.2 µl 
Eco-C-FAM primer 50 ng/µl 0.4 µl 
Hha-A primer 50 ng/µl 1.2 µl 
SuperTaq 5 U/µl 0.2 µl 
Ultra-pure water Pure 2.0 µl 






















Table 7.3 Primer sequences used for IS-typing and to amplify spa and the seven genes amplified 
in MLST 
 
Name Sequence Reference 
Primers used for IS-typing (Budding, 
Vandenbroucke-
Grauls et al. 2010) 
FirlSf 5’ CTG GAT CAC CTC CTT TCT AAG -3’ 
DUISr1 5’ AGG CAT CCA CCG TGC GCC CT -3’ 
Primers used for MLST (Enright, Day et al. 
2000) arcUP 5' TTG ATT CAC CAG CGC GTA TTG TC -3' 
arcDN 5' AGG TAT CTG CTT CAA TCA GCG -3' 
aroUP 5' ATC GGA AAT CCT ATT TCA CAT TC -3' 
aroDN 5' GGT GTT GTA TTA ATA ACG ATA TC -3' 
glpUP 5' CTA GGA ACT GCA ATC TTA ATC C -3' 
glpDN 5' TGG TAA AAT CGC ATG TCC AAT TC -3' 
gmkUP 5' ATC GTT TTA TCG GGA CCA TC -3' 
gmkDN 5' TCA TTA ACT ACA ACG TAA TCG TA -3' 
ptaUP 5' GTT AAA ATC GTA TTA CCT GAA GG -3' 
ptaDN 5' GAC CCT TTT GTT GAA AAG CTT AA -3' 
tpiUP 5' TCG TTC ATT CTG AAC GTC GTG AA -3' 
tpiDN 5' TTT GCA CCT TCT AAC AAT TGT AC -3' 
yqiUP 5' CAG CAT ACA GGA CAC CTA TTG GC -3' 
yqiDN 5' CGT TGA GGA ATC GAT ACT GGA AC -3' 
Primers used for spa typing (Hallin, Friedrich et 
al. 2009) spa1113f 5’ TAA AGA CGA TCC TTC GGT GAG -3’ 












 AFLP, IS-typing and spa data were analyzed using the BioNumerics platform (Applied 
Maths, Sint-Martens-Latem, Belgium). For AFLP and IS-typing, digitized gel images from the 
automated sequencer were analyzed using the Bionumerics software, while computerized 
sequence chromatograms were uploaded into Bionumerics for spa typing.   
 AFLP bands were assigned to classes (n = 63) allowing binary profiles to be defined 
which were then analyzed using the Dice coefficient and the un-weighted pair group method 
with arithmetic means (UPGMA) as previously described (Melles, Tenover et al. 2008; Melles, 
Schouls et al. 2009).  Clusters were defined as 80% similar and subclusters were defined at the 
86% level of similarity. Amplicons from IS-typing PCR were assigned to one of 15 band classes;  
binary profiles were generated and compared using the Dice coefficient and UPGMA as 
previously described (Budding, Vandenbroucke-Grauls et al. 2010).  Briefly, spa sequences were 
analyzed using the spa plugin for Bionumerics; newly identified types were submitted to the spa 
server for classification (spaserver2.ridom.de).  Sequence types (MLST) were defined by 
concatenating sequences with the MLST S. aureus database (www.mlst.net). 
 
7.3 Results 
 Four AFLP clusters (I-IV) and seven subclusters (Ia,b,c;IIa,b;IIIa,b) were identified.  
Canine (Dutch and Canadian) and human isolates, both methicillin resistant and susceptible, 
clustered together including isolates with identical AFLP binary band patterns (Figure 7.1).  
Human MRSA were concentrated in clusters Ia (9/51), Ib (22/51) and IIB (19/51), while MSSA 
were distributed throughout all clusters.  Clinical canine MRSA from Saskatoon were found in 
clusters Ia (7/9) and IIb (2/9), while canine MRSA from the Netherlands were found among six 








AFLP clusters broken down by origin, each coloured section is sized proportionately to the number of isolates in 
that group.  Pink corresponds to human MRSA, red to human MSSA, dark blue to colonizing S. aureus from 
Saskatoon, light blue to clinical canine MRSA from Saskatoon, light green to canine MRSA from the Netherlands 
and dark green to canine MSSA from the Netherlands.  Three non-clustering isolates, two between clusters Ic and 
IIa, a human MSSA from Saskatoon (t941) and a canine MSSA from the Netherlands (t6495), and one between 
clusters IIb and IIIa, a human MSSA from Saskatoon (t216).  The spa types, and number of isolates with each type, 




human isolates predominated in clusters Ib and IIb.  Cluster Ia was the only group containing 
isolates from all sources (Figure 7.1).       
 Forty eight IS-PRO profiles were found containing between one and 21 isolates in each.  
Canine and human isolates were distributed throughout the minimum spanning tree including 
many indistinguishable isolates (Figure 7.2).  Of the 48 IS-profiles, nine were common to human 
and canine isolates while 23 were limited to human and 16 were limited to those from dogs. 
 Fifty seven different spa types were identified including five new types: t6495, t6496 
among canine MSSA from the Netherlands, and t6646, t6651 and t6652 among human MSSA 
from Saskatoon (Table 7.4). Human MRSA were limited to 11 spa types while HC-MSSA was 
made up of 32 spa types.  Seven of nine canine MRSA isolates from Saskatoon were spa types 
common to Human MRSA (t002 n=5 and t311 n=2).  Among the 15 spa types identified in 
canine strains from the Netherlands, 10 were unique to the Netherlands, the remainder were 
found among Canadian isolates.       
 Good agreement between the techniques was observed.  When AFLP clusters were 












Figure 7.2 Minimum spanning tree of IS-types by isolate origin.   
 
Each node represents a unique isolate.  Nodes are coloured by isolate origin: Human MRSA, bright red; human 
MSSA, purple; Canadian canine colonizing, dark blue; Canadian clinical canine MRSA, bright blue; Dutch canine 


























t037 (7), t002 
(6), t108 (2), 
t127 (2), t548 
(2), t034 (1), 
t242 (1), t311 
(1) 
  
t311 (6), t012 (2), t040 (2), t065 (2), t084 
(2), t275 (2), t2728 (2), t010 (1), t026 (1), 
t034 (1), t037 (1), t085 (1), t127 (1), t132 
(1), t159 (1), t160 (1), t167 (1), t209 (1), 
t216 (1), t359 (1), t509 (1), t645 (1), t840 
(1), t941 (1), t1235 (1), t1451 (1), t1510 
(1),        t1631 (1), t1675 (1), t5595 (1),       
t5834 (1), t6646 (1), t6651 (1),       t6652 
(1)     
t002 (2), t012 (2), t189 
(2), t012 (1), t228 (1), 
t267 (1), t311 (1), t328 
(1), t338 (1), t401 (1), 








































Figure 7.3. Minimum spanning tree of IS-types by AFLP cluster. 
 
Each node represents a unique isolate.  Nodes are coloured by AFLP cluster/sub-cluster:  Ia, light green; Ib, red; Ic, 
purple; IIa, yellow; IIb, light blue; IIIa, dark blue; IIIb, brown and IV, pink.  The isolates encircled with an orange 





 Comparison of IS profiles with an existing database (courtesy of A.E. Budding) revealed 
close clustering of four isolates with confirmed MRSA ST398 samples. These four isolates all 
possessed a previously described ST398 specific band class (Budding, Vandenbroucke-Grauls et 
al. 2010).  By AFLP, these isolates were closely related belonging to the IIIa cluster (Figure 7.1).  
These isolates were all spa types commonly associated with ST398; the human MRSA was t034, 
the human MSSA were t034 and t1451 and the Dutch canine MRSA was t011; all were 
confirmed with MLST to be ST398. Two isolates with spa type t108, frequently associated with 
ST398 were identified that did not cluster with other ST398 isolates with either AFLP or IS-
PRO; following MLST this isolate was identified as ST1 (van Duijkeren, Ikawaty et al. 2008). 
 
7.4 Discussion 
 In this study three techniques were used, allowing a level of analysis not possible with 
any one of the techniques individually.  The use of IS-typing may prove useful in future 
investigation for detecting ST398; this technique is much less labor intensive and expensive than 
sequence based methods, and may be an invaluable screening test.  The sequence based typing 
methods, spa and MLST, allow comparison of data with a global database.  The ridom spa server 
currently contains over 100,000 entries comprising over 8,400 spa types from 80 countries 
(Harmsen 2010).  Through it’s MLST mapping function, the spa server allows associations 
between spa type and sequence type to be seen (Harmsen 2010).  Additionally, each entry in the 
database includes key epidemiological information including data and country of origin, and 
susceptibility to methicillin, allowing temporal and geographic comparisons (Harmsen 2010). 
 The recent emergence of MRSA in dogs has raised awareness of interspecies 




of canine and human isolates was not mutually exclusive. While several AFLP clusters (Ib and 
IIB) were dominated by human isolates, those of canine and human origin were found in all 
clusters (Figure 7.1).  Similarly, eight spa types including 55 of 144 isolates were common to 
human and canine isolates (Table 7.1).   
 Found among both people and dogs in Saskatoon (total n=24), t002, t311 and t010 are 
associated with ST5, an internationally prevalent lineage commonly isolated from human 
infections (Lowder, Guinane et al. 2009; Nulens, Stobberingh et al. 2009).  Found among human 
MRSA (n=2) and Dutch canine MSSA (n=2) in this study, t084 is another internationally 
prevalent type and is the tenth most frequently reported in the ridom database (Wu, Wang et al. ; 
Harmsen 2010).  Among the Dutch canine isolates, spa types t008, t044 and t064 are reported to 
be common among human MRSA, while t012 and t084 are common among human MSSA from 
the Netherlands (Nulens, Stobberingh et al. 2009; Grundmann, Aanensen et al. 2010).  Spa type 
t008 was most frequently found in Saskatoon, accounting for 11 of 51 (22%) of human MRSA 
tested.  The next two most frequently identified spa types in Saskatoon, t128 (n=10) and t1508 
(n=8), were rarely reported in the ridom database, 0.07% and <0.01% (eight entries) respectively 
(Harmsen 2010).  While the prevalence of spa types across Canada remains ill defined, there 
appears to be regional specificity in the types circulating.  Studies of MRSA epidemiology in 
Canada are hampered by a lack of published province-specific data (Canada 2008).  In Western 
Canada, there are important differences in locally prevalent strains that are not described in the 
current national surveillance programs (Wylie and Nowicki 2005; Gilbert, MacDonald et al. 
2006; Canada 2008).     
 Similarities were also found among Canadian and Dutch isolates.  Dutch canine isolates 




isolates, were common to the Canadian collection.  These findings corroborate previous studies 
documenting related S. aureus lineages in the Netherlands and North America (Melles, Tenover 
et al. 2008). 
 A common population of S. aureus in people and dogs indicates that bidirectional 
transmission likely occurs.  Highly similar and indistinguishable isolates from people and dogs 
have been reported, including cases of putative transmission (Simoons-Smit, Savelkoul et al. 
2000; Manian 2003; Baptiste, Williams et al. 2005; Loeffler, Boag et al. 2005).  A 2003 report 
described multiple transmission events between a dog and its diabetic owners, highlighting the 
complexity of S. aureus ecology and the potential epidemiological role of companion animals 
(Manian 2003).  Recent investigations into canine colonization with S. aureus demonstrated 
indistinguishable strains in human/dog pairs (Boost, O'Donoghue M et al. 2007; Faires, Tater et 
al. 2009).  While the direction of transmission is mainly human to dog, the public health 
implications of a canine reservoir of MRSA necessitate further study and hygienic vigilance by 
those in contact with dogs (Boost, O'Donoghue M et al. 2007; Weese and van Duijkeren 2010). 
 Since it was first described in 2005 in the Netherlands, MRSA ST398 has become 
increasingly prevalent, and is now responsible for ~30% of human MRSA infections in the 
Netherlands (van Rijen, Van Keulen et al. 2008; Bosch, de Neeling et al. 2010).  Contact with 
livestock is the main risk factor for acquiring MRSA ST398 and current epidemiological 
evidence indicates that human-human transmission, even in the hospital setting, is limited (Voss, 
Loeffen et al. 2005; van Rijen, Van Keulen et al. 2008; Cuny, Nathaus et al. 2009; Bootsma, 
Wassenberg et al. 2010).  In Canada, MRSA ST398 has been found in swine in Ontario and a 
horse from Alberta (Khanna, Friendship et al. 2008; Tokateloff, Manning et al. 2009).  Since 




Ontario but unfortunately it is not known if these individuals had contact with livestock 
(Golding, Bryden et al. 2010). 
 In this study two human MSSA ST398 (spa types t034 and t1451) were found.  One of 
these was the same spa type, t034, as the MRSA previously reported human cases from 
Saskatchewan and the horse from the neighboring province Alberta (Tokateloff, Manning et al. 
2009; Golding, Bryden et al. 2010).  There is very little information on MRSA ST398 in Canada, 
and more studies are urgently needed (Tokateloff, Manning et al. 2009).     
 A single MRSA ST398, t011, from the Dutch canine collection was identified and while 
it was possible to determine that the dog resides in Belgium, attempts to contact the owners to 
ask about livestock contact were unsuccessful.  Dogs in Germany and Canada with MRSA 
ST398 were recently reported but whether these are chance transmission events or represent the 
emergence of this lineage in dogs is unknown (Nienhoff, Kadlec et al. 2009; Floras, Lawn et al. 
2010).  Should dogs prove to be a competent host species, the Dutch search and destroy policy 
could be further challenged as the at-risk population is expanded beyond those with livestock 
contact.   
 The magnitude of the role of the canine/human link in the transmission of MRSA is ill 
defined, but may be a critical control point for interventions.  The potential negative health 
implications for dogs, the occupational hazards of veterinary work and public health concerns 
necessitate vigilance in monitoring the status of MRSA in dogs (Hanselman, Kruth et al. 2006; 
Weese and van Duijkeren 2010).  As S. aureus has little regard for species barriers, collaboration 
between veterinarians and human health care professionals is essential to define the ecology of 
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8.1 General discussion 
 The overall aim of these studies was to conduct an investigation into the ecology of 
coagulase positive staphylooccci in dogs.  The description of all aspects of such an endeavour, 
including an investigation of ill-defined factors (multiple sites of colonization and the use of 
canine plasma in the tube coagulase test), provides a template for future research.  The 
unparalleled importance of S. aureus and S. pseudintermedius for canine and human health, 
combined with the emerging challenges associated with antimicrobial resistance, necessitate 
vigilence in monitoring these potential pathogens.  Our ability to monitor the emergence of 
resistance requires examination of all relevant reservoirs and sources including clinical and 
colonizing isolates from interacting host species. 
 In the clinical microbiology laboratory, rapid and accurate methods of identification are 
desirable to provide the highest level of patient care as quickly as possible.  While the use of 
selective and differential media aids in the presumptive identification of S. aureus, colony 
morphology even on these media is insufficient for species specific identification (Rubin 2010).  
The tube coagulase test is perhaps the most important biochemical test for describing 
staphylococcal species, and is most often done using rabbit plasma (Winn, Allen et al. 2006). In 
veterinary clinical microbiology, previous studies have shown that rabbit plasma may not be 
optimal for identifying S. aureus isolated from all host species (Adesiyun and Shehu 1985).  In 
the present study, evidence supporting our hypothesis that S. aureus of canine origin will more 
rapidly coagulate canine plasma was presented.  Interestingly, the time to clot formation 
(positive test) was faster for canine plasma than rabbit plasma for human and bovine isolates as 




the limited availability of canine plasma through animal blood banks makes its use impractical 
for diagnostic use.  Fortunately, all isolates were coagulase positive using rabbit plasma 
indicating that , despite a significantly longer time until clot formation, this medium is good 
enough.  These findings indicate that the relationship between isolate origin and ability to 
coagulate various plasmas requires further investigation including large numbers of 
prospectively collected isolates to remove the bais of previous biochemical identification.  
 Despite increasing interest in the ecology of coagulase positive staphylococci in dogs, 
particularly methicillin resistant organisms, studies into canine colonization are confounded by 
inadequate knowledge of the sites of colonization.  Recently, multiple sites of S. aureus 
colonization in human beings, including people who are single site colonized were recognized 
(Batra, Eziefula et al. 2008).  Failing to sample relevant sites results in false negatives and 
underestimates prevalence, potentially leading to unfounded decisions when carriers are not 
identified in the hospital setting.  In the current study the nares, pharynx and rectum were 
sampled, and all were found to play a role in both S. aureus and S. pseudintermedius 
colonization. Single site nasal, pharyngeal and rectal colonization with S. aureus and S. 
pseudintermedius was also identified.  For S. aureus, the small number of colonized dogs 
identified (n=17) makes evaluation of the relative importance of each site difficult.  Conversely, 
the sensitivity of pharyngeal + rectal samples for S. pseudintermedius was 99.3% compared to 
sampling all three sites,  indicating that future studies of S. pseudinteremdius in dogs, may find 
adequate diagnostic sensitivity with only pharyngeal and rectal samples.   
 Recent studies in Canada have shown that the incidence of MRSA has increased rapidly 
in the last decade (Kim, Ferrato et al. 2010; Simor, Gilbert et al. 2010).  In all, nine canine 




when it was first recognized.  Methicillin resistance, resulting in pan-β-lactam resistance, renders 
many of the commonly used, safest and most effective antimicrobials useless.  Vancomycin has 
long been an important component of anti-MRSA therapy for resistant infections in human 
beings (Woodford and Livermore 2009).  This drug along with other ‘top-shelf’ drugs are 
infrequently used in dogs and should be reserved for serious infections in human beings (Weese 
2008; Woodford and Livermore 2009).   
 In this present study a collection of 126 S. aureus isolates including clinical canine 
MRSA, canine colonizing S. aureus and human clinical MRSA and MSSA.  No resistance to 
vancomycin, linezolid, daptomycin or quinupristin/dalfopristin was found in any S. aureus.  Two 
canine and eight human isolates were susceptible to all drugs tested including penicillin. The 
single colonizing MRSA was also fluoroquinolone resistant and inducibly clindamycin resistant.  
As canine MRSA is likely acquired from human beings, this it is not surprising given that the 
macrolide + fluoroquinolone resistance phenotype is common among the human MRSA tested.  
A number of multidrug resistant S. aureus were found, including a canine MRSA resistant to 
macrolides, β-lactams, tetracyclines, aminoglycosides, sulfonamides and rifampin.  Among 
Canadian MRSA isolates, gentamicin resistance has been reported among 14.5% of HA-MRSA 
and 1.3% of CA-MRSA while trimethoprim/sulfamethoxazole resistance has been found in 
13.5% of HA-MRSA and no CA-MRSA (Zhanel, Adam et al. 2011).  The rifampin resistant 
canine MRSA was the only rifampin resistant isolate identified in this study.  While rifampin 
resistance has been infrequently reported, a recent study from Barcelona, Spain suggests that 
rifampin resistant MRSA ST228 is emerging in human beings (Mick, Dominguez et al. 2010).  
Rifampin resistant ST228 was hypothesized to have emerged from MRSA ST247 (Mick, 




differs by only a single repeat from t008 and t051, spa types associated with ST247 (Mick, 
Dominguez et al. 2010; SpaServer 2011).  Whether this isolate represents the emergence of a 
previously recognized rifampin resistant lineage, or a chance event is unknown.  Seven human 
isolates resistant to macrolides, tetracyclines, β-lactams, aminoglycosides, fluoroquinolones and 
sulfonamides were also identified.   Fortunately, no isolates resistant to all commonly used non-
β-lactam drugs: clindamycin, tetracycline, trimethoprim/sulfamethoxazole and chloramphenicol 
in companion animal medicine were found.      
 Mupirocin resistance was previously reported to be very common in human MRSA from 
northern Saskatchewan (50%) (Mulvey, MacDougall et al. 2005) but in this collection only 20% 
of MRSA and 4% of MSSA isolated from human infections were mupirocin resistant.  Whether 
this difference reflects changes in mupirocin usage or geographic variation between northern 
areas and the Saskatoon Health Region is unknown. Conversely, no mupirocin resistance was 
found in any canine isolates possibly reflecting the small canine S. aureus collection, or lack of 
mupirocin use in dogs.   
 The role of PVL in the pathogenesis of human S. aureus infections remains controversial.  
Although recent evidence suggests that the importance of PVL in pathogenesis has been 
overstated, its association with CA-MRSA lineages makes screening for PVL a useful 
epidemiological tool (Boyle-Vavra and Daum 2007; Otto 2011).  Consistent with a high and 
increasing prevalence of CA-MRSA, 39% of human MRSA isolates were PVL positive (Kim, 
Ferrato et al. 2010; Simor, Gilbert et al. 2010).  The activity of PVL on neutrophils varies by 
species and the susceptibility of canine neutrophils is unknown (Loffler, Hussain et al. 2010). 





 Compared to S. aureus, relatively little is known about the antimicrobial susceptibility of 
S. pseudintermedius, particularly isolates collected from healthy colonized dogs.  At the Western 
College of Veterinary Medicine, clinical S. pseudintermedius isolates have historically remained 
overwhelmingly susceptible (Ball, Rubin et al. 2008; Rubin, Ball et al. 2011). One study recently 
reported only 7% penicillin resistance among clinical S. pseudintermedius isolates from 1986 
through 2000 (Rubin, Ball et al. 2011).  The rapid emergence of MRSP in dogs has, like MRSA 
in people, challenges the treatment of once simple infections (Ruscher, Lubke-Becker et al. 
2010).  At the WCVM the discovery of a multidrug resistant MRSP isolate (resistant to 
macrolides, aminoglycosides, fluoroquinolones, rifampin, trimethoprim/sulfamethoxazole and 
chloramphenicol) suggests that resistance has recently emerged in this region as well (Rubin and 
Gaunt 2011).  Interestingly, the S. pseudintermedius isolated from healthy dogs in the present 
study were remarkably susceptible; the most common phenotype found in 71 (46.4%) of isolates 
tested was pan-susceptibility.  Although one dog was found to carry MRSA, no MRSP carriers 
were identified in this study.  Only one multidrug resistant S. pseudintermedius was identified, 
resistant to penicillin, ampicillin, tetracycline and mupirocin.  Sampling for the present study was 
done between May and November 2008, before the aforementioned MRSP was identified 
suggesting that the emergence of resistance in S. pseudinteremdius in this region may be a very 
recent phenomenon.  The author is aware of MRSP isolated from dogs in British Columbia, 
Alberta and Saskatchewan suggesting that this organism is widespread, although perhaps not yet 
common, in western Canada.  Vigilance is needed in monitoring the emergence of antimicrobial 
resistance in this species particularly because S. pseudintermedius infections are often treated 




 The recognition of MRSA in companion animals led many to speculate on the origin of 
these organisms.  Currently, the similarity of canine and human S. aureus isolated in the same 
region suggests that transmission is occurring, primarily from people into dogs (Weese and van 
Duijkeren 2010).  In this study, indistinguishable canine and human isolates from Saskatoon 
were identified using a number of molecular techniques.  Canine isolates from the Netherlands, 
indistinguishable from Canadian isolates were also identified.  These data suggest that not only is 
human-dog transmission occurring, but that internationally prevalent lineages are present in 
Saskatoon, and the Netherlands.  The hypothesis of interspecies transmission is supported by this 
data, although it must be emphasized that this study was not designed to address the direction of 
transmission.   
 A number of human isolates belonging to the ST398 lineage (two MSSA and one MRSA) 
were identified.  This sequence type is strongly associated with pigs and although no data about 
livestock contact was available, this finding suggests that interspecies transmission of S. aureus 
in Saskatchewan is not limited to humans and dogs (Voss, Loeffen et al. 2005; Bootsma, 
Wassenberg et al. 2010).  While MRSA ST398 has been reported from humans, horses, pigs and 
dogs in Canada, relatively little is known about its epidemiology and more research is sorely 
needed (Khanna, Friendship et al. 2008; Tokateloff, Manning et al. 2009; Floras, Lawn et al. 
2010; Golding, Bryden et al. 2010).  One canine MRSA ST398 from the Netherlands was also 
identified but again, no data regarding livestock contact was available.  At this point, it is 
unknown if finding ST398 staphylococci in species other than pigs reflects a chance event, or a 






8.2 General Conclusions 
Canine plasma yields positive results significantly faster than rabbit plasma when testing S. 
aureus using the tube coagulase test. 
 
In dogs, the nares, pharynx and rectum are all sites of colonization for S. aureus and S. 
pseudintermedius.  Single site colonization of all three sites also occurs for both S. aureus and S. 
pseudintermedius. 
 
The S. pseudintermedius tested in this study were remarkably susceptible and pan-susceptibility 
was the most common phenotype identified.  These results suggest that empiric ampicillin 
(amoxicillin), clindamycin or tetracycline therapy is likely to be effective; however, the 
emergence of multi-drug resistance necessitates culture and susceptiblity testing.  Follow up 
studies including isolates collected from colonized dogs, as well as clinical laboratory 
submissions should be done to monitor antimicrobial resistance in the Saskatoon region.   
 
The antimicrobial susceptibility profiles of S. aureus were highly variable.  Although no isolates 
resistant to all of the commonly used drugs were identified, the unpredictability of resistance in 
any given isolate makes the selection of rational empiric therapy impossible.  To ensure prudent 
antimicrobial therapy, the necessity of culture and susceptibility testing must be stressed to both 
veterinarians and physicians.  Follow up studies including canine and human S. aureus isolates 




Using DNA fingerprinting techniques (AFLP, spa typing and IS-typing) it was clear that canine 
and human S. aureus do not belong to mutually exclusive populations.  The hypothesis of a 
shared population is supported by these data. 
 
Staphylococcus aureus has little regard for species barriers.  Collaboration between veterinarians 
and human health professionals is essential to further our understanding of the ecology of this 
potential pathogen. 
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